132 min read

Part III · Regulation and Integration  ·  Estimated reading time 110 minutes  ·  Prerequisites: Chapters 1, 2, 3, 12

In This Chapter

16. The Endocrine System

Hormones, Glands, and Chemical Regulation

Part III · Regulation and Integration  ·  Estimated reading time 110 minutes  ·  Prerequisites: Chapters 1, 2, 3, 12

Case File 16 — "Too Much Insulin"

Amara Osei is now thirty hours past the chest pain that brought her in. The immediate cardiac emergency is stabilized. What happens next is the part of her care that nobody performed for the previous three years: somebody sits down and orders the metabolic and endocrine studies that her chart has been quietly asking for since her last physical.

Her fasting laboratory panel, drawn at 06:15 on hospital day two:

Measurement Amara's value Reference range Read
Fasting plasma glucose 212 mg/dL (11.8 mmol/L) 70–99 mg/dL High — diabetic range
Hemoglobin A1c 7.4% < 5.7% High — ~3-month average glucose ≈ 166 mg/dL
Fasting insulin 28 µU/mL 2–12 µU/mL High
Waist circumference 96 cm (37.8 in) < 88 cm (women) High
Triglycerides 244 mg/dL < 150 mg/dL High
HDL cholesterol 38 mg/dL > 50 mg/dL (women) Low
Plasma renin activity 4.8 ng/mL/h 0.5–3.0 ng/mL/h (upright) High
Plasma aldosterone 22 ng/dL 4–21 ng/dL (upright) High
Salivary cortisol, 08:00 0.29 µg/dL 0.10–0.75 µg/dL Within range
Salivary cortisol, 23:00 0.24 µg/dL < 0.09 µg/dL High for the hour

The last two lines are the strangest and the easiest to overlook. Her cortisol is not grossly elevated at any single moment. What is abnormal is its shape across the day: the normal steep morning peak and deep midnight trough have flattened into a low plateau, phase-shifted by roughly six hours. This is the endocrine signature of twenty years of rotating night shift, and it is written into her chart in the same ink as her glucose.

Three questions to hold on to.

  1. Insulin lowers blood glucose. Amara's insulin is more than twice the upper limit of normal, and her glucose is more than twice the upper limit of normal — at the same time. How is that possible, and which of the two numbers is the disease?
  2. What does twenty years of night-shift work actually do to cortisol secretion, and why would a flattened cortisol rhythm matter to a coronary artery?
  3. Aldosterone is a salt-retaining hormone from the adrenal cortex. Amara is here for chest pain. What is aldosterone doing in a story about the heart, and why did anyone order it?

Learning Objectives

By the end of this chapter you should be able to:

  1. Compare the endocrine and nervous systems on speed, duration, specificity, mode of transmission, and mechanism of targeting, and explain where the two overlap.
  2. Classify hormones as amino-acid-based or steroid, and predict from that classification alone how each is transported, how long it survives in plasma, and where its receptor sits.
  3. Trace a second-messenger cascade from hormone binding through G protein, adenylate cyclase, cyclic AMP, and protein kinase A to a cellular response, and calculate the approximate degree of amplification.
  4. Explain direct gene activation by lipid-soluble hormones and account for its latency.
  5. Define target-cell specificity, and explain up-regulation and down-regulation of receptors as the molecular basis of hormone resistance.
  6. Distinguish humoral, neural, and hormonal stimuli for hormone release, and diagram negative feedback in a three-tier axis with a tropic hormone.
  7. Describe the two lobes of the pituitary as anatomically and functionally distinct, and explain the hypophyseal portal system as a structure→function argument.
  8. Name the six anterior pituitary hormones with their targets and principal effects, and the two posterior pituitary hormones with their sites of synthesis.
  9. Describe the thyroid follicle, the steps of thyroid hormone synthesis, and the metabolic effects of T3 and T4; contrast hypo- and hyperthyroidism as mirror images.
  10. Diagram calcium homeostasis, naming PTH's three target organs and the roles of calcitriol and calcitonin.
  11. Map the three zones of the adrenal cortex to their products, and describe the adrenal medulla as a modified sympathetic ganglion.
  12. Build the renin–angiotensin–aldosterone system from stimulus to effect, naming every organ, enzyme, and action, and state four separate ways it raises blood pressure.
  13. Describe cortisol's metabolic, cardiovascular, and immune actions and the three stages of the general adaptation syndrome.
  14. Explain glucose homeostasis as an antagonistic pair, and distinguish type 1 from type 2 diabetes as failures at different boxes of the same feedback loop.
  15. List the endocrine functions of organs not usually called endocrine glands — heart, kidney, stomach, adipose tissue, bone, and placenta — and give the hormone and its effect.
  16. Localize an endocrine lesion to the primary, secondary, or tertiary level by measuring a hormone together with its tropic hormone.

16.1 Two Control Systems, One Body

You have spent four chapters on the nervous system. It is fast, precise, and electrical. Now meet its counterpart, which is slow, diffuse, and chemical — and which controls, in the end, rather more of you.

The endocrine system is the collection of glands and scattered cells that secrete hormones: chemical messengers released into the bloodstream that travel to distant target cells and alter their activity. The word endocrine means "secreting within," and the distinction it draws is anatomical. Exocrine glands secrete through a duct onto an epithelial surface — sweat onto skin, saliva into the mouth, pancreatic enzymes into the duodenum. Endocrine glands have no ducts at all. They secrete into the interstitial fluid, from which the product diffuses into capillaries and is carried away by the blood.

That single structural difference has an enormous functional consequence. A duct delivers a secretion to one place. The bloodstream delivers a secretion to everywhere. An endocrine gland therefore cannot choose its audience by aiming; it must choose its audience by chemistry — by the fact that only some cells carry a receptor able to read the message. Hold on to that idea. It is the whole chapter in one sentence, and it will resolve Amara's first question.

The comparison, made precisely

Property Nervous system Endocrine system
Signal Electrical (action potential) then chemical (neurotransmitter) Chemical only (hormone)
Transmission Along a dedicated axon to a specific synapse Broadcast through the bloodstream
Speed of onset 1–10 milliseconds Seconds (epinephrine) to hours (thyroid hormone)
Duration of effect Milliseconds to seconds Minutes to days; some effects permanent
Targeting Anatomical — the axon reaches one place Chemical — only cells with the receptor respond
Signal strength coded by Action potential frequency Hormone concentration
Typical effectors Muscle and glands Nearly every cell type in the body
Adaptation Rapid; receptors desensitize in seconds Slow; receptor number changes over hours to days

Two entries in that table deserve more than a row.

Speed versus duration is a trade-off, not an accident. A nervous signal is fast because it runs on a pre-built wire and lasts milliseconds because the transmitter is destroyed or recaptured almost instantly. A hormonal signal is slow because it must be synthesized (or released from storage), enter the circulation, mix with roughly five liters of blood, and find its receptors — and it lasts because nothing removes it quickly. If you need to pull your hand off a hot pan, you need the nervous system. If you need to keep your blood calcium within 0.5 mg/dL for forty years, you need the endocrine system. Neither could do the other's job.

Signal strength is coded differently, and this matters clinically. A neuron cannot make a bigger action potential — they are all-or-nothing — so it reports intensity by firing faster. An endocrine gland has no frequency to modulate; it reports intensity by secreting more. Which means that when you measure a hormone in plasma, you are reading the control system's output directly, in a way that is simply not possible for a nerve. This is why endocrinology is the most quantitative discipline in clinical medicine, and why a single tube of Amara's blood can tell you what several of her control systems are trying to do.

Thread 3 · The Body Is Integrated

The nervous and endocrine systems are usually taught as two chapters, and they are in fact one system with two output channels. The evidence is anatomical:

  • The hypothalamus, a piece of brain, is also the master endocrine gland. It manufactures hormones, and it directly controls the pituitary.
  • The adrenal medulla is developmentally a sympathetic ganglion whose neurons lost their axons and became secretory cells. It is innervated by preganglionic sympathetic fibers and responds to them by dumping epinephrine into the blood. It is a nerve that speaks by hormone.
  • The posterior pituitary is not a gland at all. It is a bundle of axon terminals belonging to hypothalamic neurons, releasing their product into capillaries instead of onto another neuron.
  • Norepinephrine is a neurotransmitter at a sympathetic synapse and a hormone in the bloodstream. Same molecule, two systems, two names, depending only on how far it travels.

The word for the overlap is neuroendocrine, and the general principle is that the nervous system handles the fast layer of control and hands off to the endocrine system for anything that must be sustained. Fight-or-flight is nervous for the first ten seconds and hormonal for the next ten minutes.

What hormones actually do

A hormone never creates a new cellular capability. It changes the rate of something the target cell can already do. There are only a few ways to do that, and every hormone in this chapter uses some combination of them:

  1. Change the permeability of the plasma membrane, or its membrane potential, by opening or closing channels.
  2. Stimulate the synthesis of proteins — usually enzymes — inside the cell.
  3. Activate or deactivate enzymes that are already present, almost always by adding or removing a phosphate group.
  4. Induce secretion of a product.
  5. Trigger mitosis or its opposite.

Notice that mechanism 3 is fast (seconds — the enzyme already exists) and mechanism 2 is slow (30 minutes to hours — a gene must be transcribed and a protein translated). You can predict a hormone's latency from knowing which of these it uses, and you will do exactly that in §16.2.

Check Your Understanding 16.1

  1. The pancreas is described as both an exocrine and an endocrine gland. Explain the anatomy behind that dual classification.
  2. A patient's blood epinephrine concentration doubles. A second patient's sympathetic nerves to the heart double their firing rate. Both hearts speed up. What is fundamentally different about how the two signals were encoded?
Show answers
  1. The pancreas contains two entirely separate secretory populations. About 98–99% of its mass is exocrine acinar tissue that makes digestive enzymes and delivers them through the pancreatic duct into the duodenum — a duct to a specific destination. Scattered through that tissue are roughly one to two million pancreatic islets, ductless clusters that secrete insulin and glucagon into surrounding capillaries and thence to the whole body. Same organ, two glands, distinguishable at a glance under a microscope (see the Histology sidebar in §16.8).
  2. The epinephrine signal is encoded as a concentration — an amplitude code — broadcast to every cell in the body, of which only those bearing beta-1 adrenergic receptors respond. The sympathetic signal is encoded as an action potential frequency — a rate code — delivered down a specific axon to a specific location. The first is slower to start, slower to stop, and unavoidably systemic; the second is nearly instantaneous, terminates the moment firing stops, and affects only the innervated tissue. This is why the same molecule can be used for both a scalpel and a broadcast.

16.2 Hormone Chemistry Determines Everything

If you learn one organizing fact in this chapter, make it this one: hormones come in two chemical classes, and a hormone's class predicts almost everything else about it.

Predict This

Steroid hormones are made from cholesterol and are therefore lipid-soluble; peptide hormones are chains of amino acids and are water-soluble. Blood plasma is mostly water. The plasma membrane of a cell is a lipid bilayer.

Before reading on, predict three things: (a) which class can travel dissolved in plasma and which needs help; (b) which class can walk straight through a plasma membrane and which cannot; and (c) therefore, where each class's receptor must be located.

(Answers: peptides dissolve freely, steroids need a carrier protein; steroids cross the membrane, peptides cannot; therefore peptide receptors must be on the cell surface and steroid receptors must be inside the cell. Every other difference in this section follows from these three.)

Class 1 · Amino-acid-based hormones

By count, most hormones are built from amino acids. They subdivide by size:

  • Amines — single modified amino acids. Epinephrine, norepinephrine, and dopamine are made from tyrosine; melatonin from tryptophan; thyroid hormone also from tyrosine (but see below — thyroid hormone is the great exception in this classification).
  • Peptides — short chains, roughly 3 to 200 amino acids. Antidiuretic hormone (9 amino acids), oxytocin (9), glucagon (29), insulin (51, in two chains), parathyroid hormone (84), growth hormone (191).
  • Proteins and glycoproteins — long chains, often with sugar groups attached: TSH, FSH, LH.

All of them, with the single exception of thyroid hormone, are water-soluble.

Class 2 · Steroid hormones

Steroids are synthesized from cholesterol and retain its four fused carbon rings. Only two organs make them: the adrenal cortex (cortisol, aldosterone, adrenal androgens) and the gonads (testosterone, estrogens, progesterone). The kidney performs the final activation step for calcitriol, the active form of vitamin D, which is a steroid in every functional sense (Chapter 6).

All of them are lipid-soluble.

The exception that proves the rule

Thyroid hormone is built from two tyrosines — chemically an amino acid derivative — but the addition of four iodine atoms makes the finished molecule strongly lipid-soluble. It therefore behaves in every physiological respect like a steroid: it travels bound to a carrier protein, it has a long half-life, its receptor is inside the nucleus, and it works by changing gene transcription. When you sort hormones for exam purposes, sort them by solubility, not by chemical family, and thyroid hormone stops being confusing.

 ┌─ WATER-SOLUBLE ──────────────────────┐┌─ LIPID-SOLUBLE ───────────────────┐
 │ peptides · proteins · most amines    ││ steroids · thyroid hormone (T3/T4)│
 │ insulin  glucagon  GH  TSH  ACTH     ││ cortisol   aldosterone   estrogen │
 │ FSH  LH  PRL  ADH  oxytocin  PTH     ││ progesterone  testosterone        │
 │ calcitonin  epinephrine  leptin      ││ calcitriol (vitamin D)            │
 ├──────────────────────────────────────┤├───────────────────────────────────┤
 │ TRANSPORT  dissolved FREE in plasma  ││ TRANSPORT  >95% bound to CARRIER  │
 │ HALF-LIFE  seconds → minutes         ││ HALF-LIFE  hours → days (T4 ~7 d) │
 │ RECEPTOR   PLASMA-MEMBRANE surface   ││ RECEPTOR   CYTOPLASM or NUCLEUS   │
 │ MECHANISM  2nd messenger cascade     ││ MECHANISM  direct gene activation │
 │ LATENCY    seconds                   ││ LATENCY    30 min → hours → days  │
 │ STORAGE    stored in vesicles, ready ││ STORAGE    NOT stored; made on    │
 │            for instant release       ││            demand from cholesterol│
 └──────────────────────────────────────┘└───────────────────────────────────┘

 MECHANISM A · SECOND MESSENGER          MECHANISM B · DIRECT GENE ACTIVATION
 (water-soluble hormone)                 (lipid-soluble hormone)

      hormone ●                                  steroid ●
         │ cannot enter cell                        │ diffuses straight
         ▼                                          ▼ through the bilayer
  ~~~~[RECEPTOR]~~~~~ membrane ~~~~        ~~~~~~~~~~~~~~~~~ membrane ~~~~~~
         │ conformational change                    │
         ▼                                          ▼
    G PROTEIN (Gs) + GTP                   binds INTRACELLULAR RECEPTOR
         │ activates                                │
         ▼                                          ▼ complex enters nucleus
   ADENYLATE CYCLASE                        ╔═══════════════════════════╗
         │                                  ║  binds HORMONE RESPONSE   ║
    ATP ─┴──► cyclic AMP  ◄── 2nd messenger ║  ELEMENT on the DNA       ║
                │                           ╚════════════╤══════════════╝
                ▼                                        ▼
        PROTEIN KINASE A                          mRNA TRANSCRIPTION
                │ adds PO4 to enzymes                     ▼
     ┌──────────┼──────────┐                       TRANSLATION on
     ▼          ▼          ▼                        ribosomes
  enzyme ON  enzyme OFF  channel opens                     ▼
                                                   NEW STRUCTURAL or
  AMPLIFICATION                                    ENZYMATIC PROTEIN
  1 hormone → ~10 G proteins → each cyclase
  makes ~10^3 cAMP → each PKA phosphorylates      NO amplification cascade,
  ~10^2 enzymes → each enzyme runs ~10^3           but ONE mRNA is translated
  reactions/s                                      many times over
        NET GAIN ≈ 10^6 to 10^8                    LATENCY is set by
        LATENCY  seconds                           transcription time

Figure 16.1 — The two hormone classes and the two signaling mechanisms that follow from their solubility.

Described: The figure is in two halves. The upper half is a two-column table contrasting water-soluble hormones — peptides, proteins, and most amines, including insulin, glucagon, growth hormone, TSH, ACTH, FSH, LH, prolactin, ADH, oxytocin, parathyroid hormone, calcitonin, epinephrine, and leptin — with lipid-soluble hormones, comprising the steroids cortisol, aldosterone, estrogen, progesterone, and testosterone, plus calcitriol and thyroid hormone. Water-soluble hormones travel dissolved free in plasma, have half-lives of seconds to minutes, bind receptors on the plasma membrane surface, act through second-messenger cascades with latencies of seconds, and are stored pre-made in secretory vesicles for instant release. Lipid-soluble hormones travel more than ninety-five percent bound to carrier proteins, have half-lives of hours to days with thyroxine at about seven days, bind receptors in the cytoplasm or nucleus, act by direct gene activation with latencies of thirty minutes to days, and are not stored but synthesized on demand from cholesterol. The lower half diagrams the two mechanisms side by side. In mechanism A, a water-soluble hormone binds a surface receptor, which changes shape and activates a G protein carrying GTP, which activates adenylate cyclase, which converts ATP into cyclic AMP, the second messenger; cyclic AMP activates protein kinase A, which phosphorylates target enzymes, switching some on, some off, and opening ion channels. Each step multiplies the signal — roughly ten G proteins per hormone, a thousand cyclic AMP molecules per cyclase, a hundred enzymes phosphorylated per kinase — for a net amplification of about one million to one hundred million fold within seconds. In mechanism B, a lipid-soluble hormone diffuses through the membrane, binds an intracellular receptor, and the hormone–receptor complex enters the nucleus and binds a hormone response element on the DNA, initiating transcription of messenger RNA and then translation into a new structural or enzymatic protein. There is no enzymatic cascade, but a single messenger RNA is translated many times; the latency is set by how long transcription and translation take.

Solubility determines transport, and transport determines half-life

A water-soluble hormone dissolves in plasma and circulates free. Free hormone is immediately available to bind receptors — and immediately available to be filtered by the kidney and chewed up by plasma and hepatic enzymes. Insulin's half-life in plasma is about 6 minutes. Epinephrine's is under 2 minutes. ADH's is roughly 15 minutes.

A lipid-soluble hormone cannot dissolve in plasma at useful concentrations, so it travels attached to a transport protein — corticosteroid-binding globulin for cortisol, thyroxine-binding globulin for T4, sex hormone-binding globulin for the gonadal steroids, and albumin for everything else in a pinch. Typically 95–99% of the circulating hormone is bound at any moment.

Two consequences follow, and both are clinically enormous.

First: only the free fraction is active. A bound hormone cannot cross a membrane and cannot bind a receptor. It is inert cargo. The bound pool functions as a circulating reservoir that buffers the free concentration — as free hormone is used up, bound hormone dissociates to replace it. This is why a thyroid panel reports free T4 rather than total T4: pregnancy and oral estrogens raise thyroxine-binding globulin, which raises total T4 substantially while the free, active fraction, and the patient, remain entirely normal.

Second: binding protects the hormone from clearance. Bound hormone is not filtered at the glomerulus and is not accessible to degrading enzymes. Half-lives rise accordingly: cortisol about 90 minutes, aldosterone about 20 minutes, testosterone a few hours, T4 approximately seven days. That last number explains a great deal of clinical practice — you cannot usefully recheck thyroid function until roughly six weeks after a dose change, because the hormone takes that long to reach a new steady state.

Target cell specificity: the receptor is the address

Every cell in Amara's body is bathed in every hormone she makes. Insulin reaches her cornea, her eardrum, and her toenail bed as surely as it reaches her muscle. Why does only some of her respond?

Because a hormone can only act on a cell that expresses the receptor for it. Three conditions must all be met for a target cell to respond:

  1. The hormone is present in the blood at an adequate concentration.
  2. The cell expresses receptors that bind that hormone with high affinity and specificity.
  3. Those receptors are functionally coupled to a downstream pathway inside that cell.

The third condition is easy to forget and is where a great deal of pathology lives. A receptor can be present, and can bind hormone perfectly, and yet be disconnected from what happens next.

Note also that the same hormone can produce opposite effects in different tissues, purely because the tissues wire the receptor to different machinery. Epinephrine binding beta-2 receptors on bronchiolar smooth muscle causes relaxation — the airway opens. Epinephrine binding alpha-1 receptors on cutaneous arteriolar smooth muscle causes contraction — the vessel closes. One molecule, two receptor subtypes, opposite outcomes, in the same person at the same moment. The message is not in the hormone. The message is in the receptor.

Up-regulation and down-regulation — the foundation of resistance

Receptor number is not fixed. Cells continuously insert and internalize receptors, and they adjust the number in response to how much hormone they have been seeing.

  • Up-regulation — persistently low hormone levels cause a target cell to synthesize more receptors, increasing its sensitivity. A denervated skeletal muscle spreads acetylcholine receptors across its entire surface within days, which is why it becomes hypersensitive to circulating acetylcholine.
  • Down-regulation — persistently high hormone levels cause a target cell to internalize and destroy receptors, and to uncouple the remaining ones from their downstream pathways, decreasing its sensitivity.

Down-regulation is a sensible piece of engineering. It prevents a target from being driven into the ground by a signal that will not stop, and it keeps the cell operating in the responsive middle of its dose–response curve rather than saturated at the top. It is also a trap, because the control loop that regulates the hormone does not know it is happening. The gland measures the variable, not the response. If the variable does not correct, the gland secretes more. If the target has down-regulated, more hormone produces no more effect — and so the gland secretes more still.

Thread 2 · Homeostasis Is the Master Concept

Follow that loop one more turn and you have arrived, three sections early, at Amara's answer.

Glucose is high → beta cells secrete insulin → muscle and liver have down-regulated and uncoupled their insulin receptors → glucose stays high → beta cells secrete more insulin → chronic hyperinsulinemia drives further down-regulation → glucose stays high.

Amara's fasting insulin of 28 µU/mL is not a laboratory error and it is not the disease. It is the measured output of a control system that is working exactly as designed, applying maximum effort to a variable that will not move, because the failure is not in the sensor, not in the controller, and not in the signal. The failure is at the effector, and no amount of signal fixes a broken effector. Recall the table in §1.5: this is a target/effector failure, and it has a name — insulin resistance.

Keep that structure in mind. You will meet it again in the heart that cannot answer a sympathetic signal, in the kidney that cannot answer ADH, and in the bone that cannot answer PTH. When a hormone is high and its effect is absent, suspect the receptor.

A note on how hormones interact

Rarely does one hormone act on a tissue alone. Three interaction patterns recur:

Interaction Definition Example
Permissiveness One hormone must be present for another to have its full effect Thyroid hormone is required for epinephrine's full lipolytic and cardiac effect; reproductive hormones cannot act normally without it
Synergism Two hormones together produce an effect greater than the sum of their separate effects Glucagon and epinephrine together raise blood glucose more than the arithmetic sum of each alone
Antagonism One hormone opposes another's action Insulin lowers glucose; glucagon, cortisol, GH, and epinephrine raise it

Permissiveness explains a clinical pattern that otherwise looks like magic. A patient with untreated hypothyroidism responds poorly to catecholamines, tolerates cold badly, and does not mobilize fat normally — not because thyroid hormone does those jobs itself, but because it maintains the receptors and enzymes through which other hormones do them. A permissive hormone is the stagehand, not the actor, and you only notice it when it leaves.

Check Your Understanding 16.2

  1. A drug blocks all protein synthesis in a cell. Which hormone's effect would be abolished first: epinephrine's on hepatic glycogen breakdown, or aldosterone's on renal sodium channels? Why?
  2. A patient with normal thyroid function is started on an oral estrogen. Her total T4 rises above the reference range but her free T4 and TSH are normal, and she has no symptoms. Explain.
  3. Why would a drug company designing a long-acting insulin want to slow its absorption from the injection site rather than change the molecule's plasma half-life?
Show answers
  1. Aldosterone's. Aldosterone is a steroid; it works by direct gene activation, so its entire effect depends on transcribing and translating new epithelial sodium channels and sodium-potassium pumps. Block protein synthesis and aldosterone does nothing. Epinephrine works through a cyclic AMP cascade that phosphorylates enzymes already present in the cell — glycogen phosphorylase is sitting there waiting — so its effect on glycogenolysis survives a protein synthesis block for as long as the existing enzymes last. This is the practical difference between the two mechanisms, and it is also why steroid effects take 30 minutes to hours while catecholamine effects take seconds.
  2. Estrogen increases hepatic synthesis of thyroxine-binding globulin. More carrier protein means more bound hormone in circulation, so total T4 rises. But the bound fraction is inert, and the pituitary regulates against free T4 — which the feedback loop has held exactly where it was, briefly increasing secretion until the enlarged bound pool filled up. Free T4 normal, TSH normal, patient normal. This is the single most common cause of a "abnormal" total T4 in a healthy person and the reason free T4 is the test that is ordered.
  3. Because insulin's plasma half-life of about 6 minutes is set by receptor-mediated uptake and hepatic and renal degradation — processes that are hard to alter without destroying the molecule's ability to bind its receptor. It is far easier to control the rate of entry into the plasma. Long-acting insulins are engineered to precipitate or self-associate in the subcutaneous tissue and dissolve slowly, so absorption, not clearance, becomes the rate-limiting step. The plasma concentration then reflects the release rate, giving a flat 24-hour profile from a molecule that individually still disappears in minutes.

16.3 Control of Hormone Release

A hormone that was secreted continuously at a fixed rate would be useless. Regulation requires that secretion change in response to something. Endocrine glands are stimulated in exactly three ways.

The three stimuli

Humoral stimuli — the gland responds directly to the concentration of an ion or nutrient in the blood. This is the simplest possible arrangement: the sensor and the control center are the same cell.

  • Parathyroid chief cells sense falling blood calcium and secrete PTH.
  • Pancreatic beta cells sense rising blood glucose and secrete insulin.
  • Adrenal zona glomerulosa cells sense rising blood potassium and secrete aldosterone.

Neural stimuli — nerve fibers stimulate the gland directly.

  • Preganglionic sympathetic fibers stimulate the adrenal medulla to release epinephrine and norepinephrine during the fight-or-flight response.
  • Hypothalamic neurons fire to release oxytocin and ADH from their axon terminals in the posterior pituitary.

Hormonal stimuli — one hormone stimulates the release of another. Hormones that exist mainly to control other endocrine glands are called tropic hormones (from tropos, a turn or direction — they "direct" another gland).

  • Hypothalamic releasing hormones stimulate the anterior pituitary.
  • Anterior pituitary tropic hormones stimulate the thyroid, adrenal cortex, and gonads.

Most glands use more than one. Insulin release is primarily humoral but is modulated by parasympathetic and sympathetic input and amplified by gut hormones. Aldosterone is under humoral control by potassium, hormonal control by angiotensin II, and weak tropic control by ACTH — three inputs into one cell type, which is precisely why aldosterone can serve as both an electrolyte hormone and a blood-pressure hormone.

Negative feedback is the universal pattern

Almost every endocrine loop in the body is a negative feedback loop of the architecture you built in §1.5: the response opposes the stimulus, so the response switches itself off.

  • Glucose rises → insulin secreted → glucose falls → insulin secretion falls.
  • Calcium falls → PTH secreted → calcium rises → PTH secretion falls.
  • Blood volume falls → renin, then aldosterone → sodium and water retained → volume rises → renin falls.

There is exactly one important endocrine positive feedback loop in the body: oxytocin in labor, where cervical stretch drives oxytocin release, which strengthens contractions, which stretches the cervix further. It terminates when the baby is delivered (Chapter 28). A second, the estrogen surge that triggers the LH surge at mid-cycle, is genuinely positive for about 36 hours before reverting (Chapter 27). Everything else is negative, and if you cannot find the negative loop in a new endocrine system you are reading about, you have not finished reading.

Three-tier axes and the logic of tropic hormones

The most important endocrine systems are built as three-level chains: hypothalamus → anterior pituitary → peripheral gland → hormone, with the final hormone feeding back to inhibit the two levels above it.

                    THE THREE-TIER AXIS  (general form)

     ╔══════════════════════════════════════════╗
     ║  TIER 1 · HYPOTHALAMUS                   ║ ◄──────────┐
     ║  integrates: stress, temperature, light, ║            │
     ║  emotion, circadian clock, nutrient      ║            │
     ║  status, and feedback                    ║            │
     ╚═══════════════════╤══════════════════════╝            │
                         │ RELEASING HORMONE                 │
                         │ (TRH, CRH, GnRH, GHRH)            │  LONG-LOOP
                         │ travels the HYPOPHYSEAL           │  NEGATIVE
                         ▼ PORTAL SYSTEM — a short           │  FEEDBACK
     ╔══════════════════════════════════════════╗ private    │  (the final
     ║  TIER 2 · ANTERIOR PITUITARY             ║ pipeline   │  hormone
     ║  amplifies and converts the signal into  ║            │  inhibits
     ║  a systemic tropic hormone               ║ ◄──────┐   │  BOTH tiers
     ╚═══════════════════╤══════════════════════╝        │   │  above it)
                         │ TROPIC HORMONE                │   │
                         │ (TSH, ACTH, FSH/LH)           │   │
                         │ travels the general            │  SHORT-LOOP
                         ▼ circulation                    │  FEEDBACK
     ╔══════════════════════════════════════════╗         │   │
     ║  TIER 3 · PERIPHERAL GLAND               ║         │   │
     ║  thyroid · adrenal cortex · gonad        ║         │   │
     ╚═══════════════════╤══════════════════════╝         │   │
                         │                                 │   │
                         ▼ EFFECTOR HORMONE                │   │
              ┌──────────────────────┐                     │   │
              │  T3/T4 · CORTISOL ·  ├─────────────────────┘   │
              │  ESTROGEN/TESTOST.   ├─────────────────────────┘
              └──────────┬───────────┘
                         ▼
                   TARGET TISSUES
                   throughout the body

  WHY THREE TIERS INSTEAD OF ONE?
  ─────────────────────────────────────────────────────────────────────────
  1. AMPLIFICATION.  Nanograms of CRH → micrograms of ACTH → milligrams of
     cortisol.  A thousandfold gain at each step.
  2. INTEGRATION.    Tier 1 is inside the brain, so cortisol output can be
     modulated by fear, injury, cold, hypoglycemia, and the clock.
  3. MULTIPLE CONTROL POINTS.  Feedback acts at two levels, so the loop is
     stable across a wide range of demands.
  4. DIAGNOSIS.      Measuring TIER 2 and TIER 3 together tells you WHICH
     TIER IS BROKEN.  (See §16.10.)

Figure 16.2 — The general three-tier hypothalamic–pituitary–target-gland axis with long-loop and short-loop negative feedback.

Described: A vertical chain of three boxes with feedback arrows running back up the left side. Tier one is the hypothalamus, which integrates stress, temperature, light, emotion, the circadian clock, nutrient status, and hormonal feedback, and which sends a releasing hormone — TRH, CRH, GnRH, or GHRH — down the hypophyseal portal system, a short private vascular pipeline. Tier two is the anterior pituitary, which amplifies the signal and converts it into a systemic tropic hormone — TSH, ACTH, or FSH and LH — released into the general circulation. Tier three is the peripheral gland: thyroid, adrenal cortex, or gonad. That gland secretes the effector hormone — thyroid hormone, cortisol, or the sex steroids — which acts on target tissues throughout the body and also travels back to inhibit both the pituitary and the hypothalamus, which is called long-loop negative feedback. The tropic hormone additionally inhibits the hypothalamus directly, which is called short-loop feedback. Four reasons are given for the three-tier design: amplification, since nanograms of releasing hormone produce micrograms of tropic hormone and milligrams of the final hormone; integration, since the top tier sits inside the brain and can therefore be modulated by fear, injury, cold, low blood glucose, and time of day; stability, since feedback acts at two separate levels; and diagnosis, since measuring the tier-two and tier-three hormones together identifies which tier has failed.

Look hard at reason 4, because it is the most useful diagnostic idea in endocrinology and it is developed fully in §16.10. In a three-tier axis, the pair of measurements carries information that neither measurement carries alone. Low thyroid hormone with a high TSH means the pituitary is shouting at a thyroid that cannot answer — the lesion is in the thyroid. Low thyroid hormone with a low or normal TSH means the pituitary is not shouting at all — the lesion is above the thyroid. Same peripheral hormone, opposite diagnoses, distinguished by one extra tube of blood.

Check Your Understanding 16.3

  1. Classify the stimulus for each: (a) ADH release when plasma osmolality rises; (b) insulin release after a meal; (c) epinephrine release when a car swerves toward you; (d) cortisol release in response to ACTH.
  2. A patient takes high-dose prednisone (a synthetic cortisol) for six months and then stops it abruptly. Predict what happens to her CRH, ACTH, adrenal cortex, and cortisol, in that order, and explain why the drug must be tapered instead.
Show answers
  1. (a) Humoral — osmoreceptors respond to a blood solute concentration, although the receptor is a hypothalamic neuron, so it is sometimes called neurohumoral. (b) Humoral primarily — beta cells respond to blood glucose itself — with neural and hormonal modulation. (c) Neural — preganglionic sympathetic fibers stimulate the adrenal medulla directly. (d) Hormonal — ACTH is a tropic hormone acting on the adrenal cortex.
  2. Prednisone is read by the feedback loop as cortisol. Long-loop negative feedback therefore suppresses CRH from the hypothalamus and ACTH from the pituitary for six months. Without its tropic stimulus, the zona fasciculata atrophies — tropic hormones are trophic, meaning they maintain the mass of the gland they control. When the drug stops abruptly, exogenous cortisol disappears within a day, endogenous cortisol cannot be produced because the gland has wasted and ACTH is still suppressed, and the patient has an acute adrenal crisis: hypotension, hypoglycemia, hyponatremia, hyperkalemia, vomiting, collapse. Tapering slowly allows ACTH to recover first, which then regrows the cortex — the two tiers must be brought back online in order. This is one of the most consequential practical facts in all of clinical pharmacology.

16.4 The Hypothalamus and Pituitary

The pituitary gland, or hypophysis, is about the size of a pea, weighs roughly 0.5 g, and sits in the sella turcica — the "Turkish saddle," a bony depression of the sphenoid bone — connected to the base of the brain by a stalk called the infundibulum. For a century it was called the master gland. That is only half right: the pituitary is the master's executive, and the master is the hypothalamus directly above it.

The gland has two lobes, and they are not two parts of one organ. They are two different organs of two different embryonic origins that happen to be adjacent, and almost everything confusing about the pituitary dissolves once you accept that.

Development · Two Organs in One Saddle

In the fourth week of embryonic life, two separate structures grow toward each other.

From the roof of the primitive mouth, an upward outpocketing of oral ectoderm called Rathke's pouch climbs toward the brain. It pinches off from the mouth, and it becomes the anterior lobe — the adenohypophysis, from adeno-, gland. It is true glandular epithelium, and it behaves like a gland: it manufactures hormones, it is packed with secretory cells, and it responds to chemical instruction.

From the floor of the diencephalon, a downgrowth of neural ectoderm descends to meet it. It never separates from the brain, and it becomes the posterior lobe — the neurohypophysis. It is nervous tissue: axons and glial cells called pituicytes. It contains no secretory cells at all.

Three things now make sense that otherwise would not:

  • The posterior pituitary does not make hormones; it stores and releases hormones made in the hypothalamus, because it is literally the far end of hypothalamic neurons.
  • The anterior pituitary cannot be controlled by nerves, because it has no neural connection to the brain — the epithelial tissue that formed it never was brain. It therefore needs a vascular control route, which is exactly what evolved.
  • Remnants of Rathke's pouch can persist and give rise to a craniopharyngioma, a tumor of oral-epithelial origin sitting under the brain — an anatomical absurdity until you know the embryology.

The posterior lobe: an axon terminal that opens into blood

Two hormones are released from the neurohypophysis, and both are nine-amino-acid peptides synthesized in the cell bodies of hypothalamic neurons — in the supraoptic and paraventricular nuclei — then transported down axons in the hypothalamic–hypophyseal tract and stored in terminals in the posterior lobe until an action potential arrives.

Antidiuretic hormone (ADH, vasopressin). Made mostly in the supraoptic nucleus. Released when hypothalamic osmoreceptors detect rising plasma osmolality (the threshold is about 280–285 mOsm/kg) or when baroreceptors report a large fall in blood volume or pressure. It acts on the collecting ducts of the kidney, inserting aquaporin-2 water channels into the apical membrane so that water is reabsorbed and urine is concentrated (Chapter 26). At higher concentrations it also constricts arterioles, which is where the alternative name vasopressin comes from. Ethanol inhibits ADH release, which is the entire explanation for the diuresis of a night of drinking; nicotine stimulates it.

Oxytocin. Made mostly in the paraventricular nucleus. Acts on uterine smooth muscle to produce strong contractions during labor, and on the myoepithelial cells around the mammary alveoli to eject milk. Both are positive-feedback-driven: cervical stretch drives labor, suckling drives the milk-ejection reflex (Chapter 28).

Clinical Connection · Diabetes Insipidus versus SIADH — One Hormone, Two Directions

These two disorders are ADH deficiency and ADH excess, and comparing them teaches the hormone better than either alone.

Diabetes insipidus SIADH
ADH activity Too little Too much
Cause Central: hypothalamic/pituitary damage, head trauma, surgery. Nephrogenic: kidney cannot respond (lithium, hypercalcemia) Small-cell lung cancer secreting ADH ectopically; CNS disease; many drugs; pain and nausea
Urine Enormous — 3 to 20 L/day, dilute, osmolality < 300 mOsm/kg Scant, inappropriately concentrated
Plasma sodium High (hypernatremia) Low (hyponatremia)
Plasma osmolality High Low
Thirst Severe, unrelenting Often absent
Treatment Desmopressin (central); address cause (nephrogenic) Fluid restriction; ADH receptor antagonist

Two teaching points. First, the word diabetes means "siphon" and refers to large urine volumes, not to sugar — diabetes insipidus is tasteless urine, diabetes mellitus is honey-sweet urine. They share a symptom and nothing else. Second, note the distinction between central and nephrogenic DI: the same clinical picture from a failure of the signal versus a failure of the target. That is the §16.2 distinction again, and it is tested exactly the same way — give desmopressin and see whether the kidney responds. If it does, the signal was missing. If it does not, the receptor was.

The anterior lobe and its private circulation

The anterior pituitary is a true gland, but it receives no significant nerve supply from the hypothalamus. So how does a hypothalamic neuron give it an order?

It could secrete a releasing hormone into the general circulation and let it come back around. That would be catastrophically inefficient: five liters of blood would dilute a nanogram of CRH into nothing, every other tissue in the body would be exposed to it, and hepatic and renal clearance would destroy it before it arrived. The problem is one of concentration and privacy.

The solution is the hypophyseal portal system, and it is one of the most elegant pieces of structure→function reasoning in the body.

                THE HYPOPHYSEAL PORTAL SYSTEM  (sagittal view)

     HYPOTHALAMUS
     ┌───────────────────────────────────────────────┐
     │  neurosecretory cell bodies                    │
     │    ● ● ●  ── make releasing / inhibiting       │
     │      │      hormones (TRH, CRH, GnRH,          │
     │      │      GHRH, somatostatin, dopamine)      │
     │      ▼                                          │
     │  ╔════════════════════════════╗                │
     │  ║ PRIMARY CAPILLARY PLEXUS   ║ ← hormones are │
     │  ║ (in the median eminence,   ║   secreted     │
     │  ║  base of the infundibulum) ║   DIRECTLY     │
     │  ╚══════════╤═════════════════╝   into blood   │
     └─────────────┼─────────────────────────────────┘
                   │
          ╔════════▼═══════════╗   ◄── this is the trick: blood passes
          ║ HYPOPHYSEAL PORTAL ║       from one capillary bed to a
          ║ VEINS              ║       SECOND capillary bed WITHOUT
          ║ (down the stalk)   ║       returning to the heart
          ╚════════╤═══════════╝
                   │                          hypothalamic hormone
     ┌─────────────▼─────────────────┐        concentration here is
     │ ╔═══════════════════════════╗ │        1,000–10,000× higher
     │ ║ SECONDARY CAPILLARY       ║ │        than in systemic blood
     │ ║ PLEXUS  (anterior lobe)   ║ │
     │ ╚═══════════╤═══════════════╝ │
     │             │ bathes           │      ┌── POSTERIOR LOBE ──────┐
     │  ○ somatotrophs   → GH         │      │  axon terminals of     │
     │  ○ thyrotrophs    → TSH        │      │  hypothalamic neurons  │
     │  ○ corticotrophs  → ACTH       │      │  ● ADH  ● oxytocin     │
     │  ○ gonadotrophs   → FSH, LH    │      │  released into a       │
     │  ○ lactotrophs    → PRL        │      │  SEPARATE, ordinary    │
     │       ANTERIOR LOBE            │      │  capillary bed         │
     └────────────┬──────────────────┘      └───────────┬────────────┘
                  ▼                                     ▼
        tropic hormones into the                ADH and oxytocin into
        GENERAL CIRCULATION                     the GENERAL CIRCULATION

  A PORTAL SYSTEM = two capillary beds in series joined by a vein.
  The body builds only three: this one, the hepatic portal system
  (gut → liver, Ch. 23), and the renal peritubular system (Ch. 26).
  In every case the purpose is the same — deliver a concentrated
  message from bed 1 to bed 2 without diluting it in the whole body.

Figure 16.3 — The hypophyseal portal system: why the hypothalamus can whisper to the anterior pituitary.

Described: A sagittal schematic of the hypothalamus and pituitary. In the hypothalamus, neurosecretory cell bodies manufacture releasing and inhibiting hormones — thyrotropin-releasing hormone, corticotropin-releasing hormone, gonadotropin-releasing hormone, growth hormone-releasing hormone, somatostatin, and dopamine — and send axons down to the median eminence at the base of the infundibulum, where they secrete those hormones directly into a primary capillary plexus. Blood leaving that plexus does not return to the heart; it drains into hypophyseal portal veins running down the pituitary stalk and then into a second capillary plexus inside the anterior lobe, where hypothalamic hormone concentrations are a thousand to ten thousand times higher than they would be in systemic blood. That blood bathes five cell types: somatotrophs making growth hormone, thyrotrophs making TSH, corticotrophs making ACTH, gonadotrophs making FSH and LH, and lactotrophs making prolactin. Their tropic hormones then enter the general circulation. Shown separately to the right, the posterior lobe contains only the axon terminals of hypothalamic neurons releasing ADH and oxytocin into an ordinary, unconnected capillary bed. A note defines a portal system as two capillary beds in series joined by a vein, states that the body builds only three — this one, the hepatic portal system from gut to liver, and the renal peritubular system — and observes that in every case the purpose is to deliver a concentrated message from the first bed to the second without diluting it in the whole body.

The portal system is a private, short, high-concentration delivery line. A picogram of hypothalamic hormone released into a few microliters of portal blood arrives at the pituitary at a concentration thousands of times higher than it could ever reach systemically, and it arrives in seconds. Nothing else in the body is exposed to it. That is the whole design.

It also explains a clinical fact that looks bizarre otherwise. If the pituitary stalk is severed by trauma or compressed by a tumor, prolactin rises while every other anterior pituitary hormone falls. Why would cutting the control line make one hormone go up? Because prolactin is the only anterior pituitary hormone whose dominant hypothalamic control is inhibitory — the hypothalamus continuously sends dopamine down the stalk to hold lactotrophs in check. Cut the stalk and you remove a brake, not an accelerator.

The six anterior pituitary hormones

Hormone Cell Hypothalamic control Target Principal effect
Growth hormone (GH) Somatotroph GHRH stimulates; somatostatin inhibits Liver, bone, muscle, adipose Directly: lipolysis, glucose sparing, protein anabolism. Indirectly via hepatic IGF-1: longitudinal bone growth, cell proliferation
Thyroid-stimulating hormone (TSH) Thyrotroph TRH stimulates; T3/T4 and somatostatin inhibit Thyroid follicular cells Iodine uptake, thyroid hormone synthesis and release; maintains thyroid mass
Adrenocorticotropic hormone (ACTH) Corticotroph CRH stimulates; cortisol inhibits Adrenal zona fasciculata and reticularis Cortisol and adrenal androgen synthesis; maintains cortical mass
Follicle-stimulating hormone (FSH) Gonadotroph GnRH (pulsatile) stimulates Ovarian follicles; Sertoli cells Follicle maturation and estrogen production; spermatogenesis
Luteinizing hormone (LH) Gonadotroph GnRH (pulsatile) stimulates Ovary; Leydig cells Ovulation and corpus luteum formation; testosterone production
Prolactin (PRL) Lactotroph Dopamine inhibits (dominant); TRH stimulates Mammary gland Milk synthesis after birth; suppresses GnRH

Four of the six — TSH, ACTH, FSH, LH — are tropic: their targets are other endocrine glands. GH and prolactin act directly on non-endocrine tissue, though GH's growth effects are mediated by IGF-1 from the liver, which makes it partly tropic as well.

Note the pulsatility requirement for GnRH. Gonadotrophs respond to GnRH only if it arrives in pulses roughly every 60–90 minutes. Give GnRH continuously and the gonadotrophs down-regulate and shut down within about two weeks — the §16.2 principle again, exploited deliberately as a treatment for prostate cancer and endometriosis. A hormone's pattern can carry as much information as its concentration.

Clinical Connection · Gigantism, Acromegaly, and What a Closed Growth Plate Means

A benign somatotroph adenoma secretes growth hormone autonomously — outside feedback control. The clinical picture depends entirely on one anatomical fact: whether the epiphyseal growth plates are still open (Chapter 6).

Before plate closure — excess GH drives longitudinal growth of the long bones, producing gigantism: normal proportions, extraordinary height, sometimes over 2.4 m.

After plate closure — longitudinal growth is impossible because the cartilage plate has been replaced by bone. GH's effects are diverted into appositional bone growth and soft tissue, producing acromegaly (akron, extremity + megas, large): the hands and feet broaden, the mandible protrudes and the teeth separate, the brow ridges and nose enlarge, the tongue thickens, the voice deepens as the larynx grows, and the skin coarsens. Patients often notice first that a wedding ring no longer fits, or that shoe size increased in adulthood.

Systemic consequences follow from GH's metabolic actions: insulin resistance and diabetes in about one-quarter of patients, because GH is a counter-regulatory hormone opposing insulin; hypertension; cardiomyopathy; carpal tunnel syndrome from soft-tissue swelling in a fixed tunnel; and sleep apnea from pharyngeal tissue overgrowth.

The lesson worth carrying: the same hormone excess produces two entirely different diseases depending on a piece of anatomy. That is Thread 1 stated as a clinical diagnosis.

Imaging · Looking at the Pituitary

The pituitary sits in the sella turcica, surrounded by bone below and by the cavernous sinuses and optic chiasm above — a region where a 6 mm difference in tumor size changes management.

MRI with gadolinium contrast is the modality of choice, for reasons that follow directly from physics. The gland is soft tissue against bone and air-filled sinuses; CT's strength is density discrimination, which does not help here, and the surrounding skull base produces beam-hardening artifact. MRI has superb soft-tissue contrast and no bone artifact. Thin coronal and sagittal slices show the gland, the stalk, the optic chiasm draped over it, and the carotid arteries running through the cavernous sinuses on each side.

What is looked for: a microadenoma (< 10 mm) appears as a focus that enhances more slowly than normal gland, so it looks dark on early post-contrast images. A macroadenoma (≥ 10 mm) is judged by what it is pressing on. Upward extension compresses the optic chiasm, where the fibers from the nasal half of each retina cross — producing bitemporal hemianopsia, loss of both outer visual fields, because those fields project to the nasal retinae (Chapter 15). A patient who has been bumping into things on both sides and whose periphery has quietly disappeared may have a pituitary tumor, and the visual field test that finds it costs almost nothing.

Check Your Understanding 16.4

  1. Why can a hypothalamic lesion cause deficiency of five anterior pituitary hormones while raising the sixth?
  2. A neurosurgeon removes a pituitary macroadenoma through the nose and sphenoid sinus. In the days afterward the patient's urine output rises to 8 L/day and her plasma sodium climbs to 152 mEq/L. What has happened, and which lobe is implicated?
  3. Growth hormone is highest during deep sleep and after exercise, and is suppressed by hyperglycemia. Amara has 20 years of fragmented daytime sleep, no regular exercise, and a fasting glucose of 212 mg/dL. Predict what her GH secretion looks like.
Show answers
  1. Because five of the six are controlled by stimulating releasing hormones (GHRH, TRH, CRH, GnRH) delivered down the portal system, so losing hypothalamic input removes their drive and they fall. Prolactin's dominant hypothalamic control is inhibitory — continuous dopamine — so losing hypothalamic input removes a brake and prolactin rises. The pattern "everything down except prolactin, which is up" is characteristic of stalk or hypothalamic disease.
  2. Central diabetes insipidus from injury to the posterior lobe or, more often, to the hypothalamic–hypophyseal tract in the stalk. ADH release has stopped, so the collecting ducts cannot insert aquaporins, water is lost in dilute urine, and plasma sodium and osmolality rise. This is a common and usually transient complication of transsphenoidal surgery, treated with desmopressin while the tract recovers. The posterior lobe is implicated, and note that it is affected precisely because it is neural tissue continuous with the brain, which the anterior lobe is not.
  3. Suppressed on all three counts. GH is secreted in pulses that are largest during slow-wave sleep; her sleep is fragmented and circadian-misaligned, so the nocturnal pulse is blunted. Exercise is a potent GH stimulus she is not receiving. And sustained hyperglycemia directly suppresses somatotrophs. The expected result is a low 24-hour integrated GH output — which matters because GH is a lipolytic, protein-anabolic hormone, so its loss favors visceral fat accumulation and loss of lean mass, both of which worsen the insulin resistance that helped suppress it. Another loop that reinforces itself.

16.5 The Thyroid Gland

The thyroid is a butterfly-shaped gland of two lobes joined by a narrow isthmus, sitting on the anterior trachea just inferior to the larynx. It weighs 20–30 g and is the largest pure endocrine gland in the body. It is also the only endocrine gland that stores its product extracellularly, in a form that would take months to exhaust — an unusual design that makes perfect sense once you know what the hormone does.

Histology · The Thyroid Follicle Is a Storage Tank

Put a thyroid section under a microscope and you see something you will see nowhere else: the tissue is made of hundreds of thousands of hollow spheres.

Each follicle is a single layer of cuboidal follicular cells enclosing a central lumen filled with a viscous, pink-staining, homogeneous material called colloid. Colloid is not debris. It is a concentrated solution of thyroglobulin, a large glycoprotein rich in tyrosine residues, and it is the stored, unfinished form of thyroid hormone. Roughly a two- to three-month supply sits in those lumens at any moment.

Two features are diagnostic and change with activity:

  • In a resting gland the follicular cells are flat to low cuboidal and the colloid is abundant and evenly stained.
  • In a stimulated gland — high TSH — the cells become tall columnar, and reabsorption lacunae appear as pale scalloped bays at the colloid's edge where cells are endocytosing it. The colloid pool shrinks. You can literally read the TSH level off the shape of the cells.

Squeezed into the spaces between the follicles are pale, larger parafollicular cells (C cells), which never touch the colloid because they have nothing to do with it. They make calcitonin, an entirely separate hormone about calcium. Two endocrine organs share one anatomical gland, and the microscope is what separates them.

Making thyroid hormone: the only human use of iodine

Thyroid hormone is the sole reason your body requires dietary iodine. The synthesis runs in six steps, and it is worth following each because every step is a place where drugs and disease act.

              THYROID HORMONE SYNTHESIS — ONE FOLLICLE

   BLOOD           FOLLICULAR CELL              FOLLICLE LUMEN (COLLOID)
  ────────┬──────────────────────────────┬────────────────────────────────
          │                              │
  iodide  │  ① IODIDE TRAPPING           │
   (I⁻)   │  Na⁺/I⁻ symporter pumps I⁻   │
   ●──────┼─►into the cell AGAINST a     │
          │  gradient ~30:1 (active,     │
          │  ATP-dependent)              │
          │            │                 │
          │            ▼                 │
  amino   │  ② THYROGLOBULIN SYNTHESIS   │
  acids   │  rough ER + Golgi build TG,  │  ③ EXOCYTOSIS of TG
   ●──────┼─►a huge glycoprotein with    ├──────────►  ● ● ● ● ● ●
          │  ~120 tyrosine residues      │            colloid pool
          │                              │
          │  ④ OXIDATION + IODINATION    │
          │  THYROID PEROXIDASE at the   │   I⁻ → I₂  then attached to
          │  apical membrane oxidises    ├──►  tyrosines on TG:
          │  I⁻ and attaches it          │     1 iodine = MIT
          │  (blocked by methimazole /   │     2 iodine = DIT
          │   propylthiouracil)          │
          │                              │
          │  ⑤ COUPLING                  │   DIT + DIT ──► T4 (thyroxine)
          │  peroxidase joins iodinated  ├──►  MIT + DIT ──► T3
          │  tyrosines while still on TG │     (still bound to TG —
          │                              │      this IS the stored form)
          │                              │
          │  ⑥ ENDOCYTOSIS + RELEASE     │
          │  TSH triggers uptake of      │◄── TSH
   T4 ●◄──┤  colloid droplets; lysosomes │
   T3 ●◄──┤  cleave T4 and T3 off TG;    │
   90:10  │  they diffuse into blood     │
          │                              │

  IN THE BLOOD:  99.97% of T4 is bound to thyroxine-binding globulin,
                 transthyretin, and albumin.  Half-life T4 ≈ 7 days.

  IN THE TARGET: ~85% of active T3 is made OUTSIDE the thyroid, by
                 5'-deiodinase removing one iodine from T4.
                 T4 = the PROHORMONE and the reservoir
                 T3 = the ACTIVE hormone, ~4× more potent, half-life 1 day
                 Reverse T3 (rT3) = inactive; made preferentially during
                 illness and starvation to lower metabolic rate.

Figure 16.4 — Thyroid hormone synthesis, from iodide trapping to the release of T4 and T3.

Described: A three-column diagram showing blood on the left, a follicular cell in the middle, and the colloid-filled follicle lumen on the right, with six numbered steps. Step one, iodide trapping: a sodium–iodide symporter actively pumps iodide from blood into the follicular cell against a concentration gradient of roughly thirty to one, using ATP. Step two, thyroglobulin synthesis: rough endoplasmic reticulum and Golgi build thyroglobulin, a very large glycoprotein containing about one hundred and twenty tyrosine residues. Step three: thyroglobulin is secreted by exocytosis into the lumen, forming the colloid pool. Step four, oxidation and iodination: the enzyme thyroid peroxidase, sitting at the apical membrane, oxidises iodide and attaches it to tyrosine residues on thyroglobulin — one iodine makes monoiodotyrosine, two makes diiodotyrosine; this step is the target of the antithyroid drugs methimazole and propylthiouracil. Step five, coupling: peroxidase joins iodinated tyrosines while they are still attached to thyroglobulin, two diiodotyrosines forming thyroxine, or T4, and a monoiodotyrosine plus a diiodotyrosine forming T3; this thyroglobulin-bound form is the stored form. Step six: TSH triggers endocytosis of colloid droplets back into the cell, where lysosomal enzymes cleave T4 and T3 free, and they diffuse into the blood in a ratio of about ninety to ten. Notes record that in blood, 99.97 percent of T4 is bound to thyroxine-binding globulin, transthyretin, and albumin, giving a half-life near seven days; and that in target tissues about eighty-five percent of the active hormone T3 is produced outside the thyroid by 5-prime-deiodinase removing one iodine from T4, making T4 the prohormone and reservoir and T3 the active hormone, roughly four times more potent with a one-day half-life. Reverse T3 is an inactive product made preferentially during illness and starvation to lower metabolic rate.

Three points from that figure repay attention.

The gland stores months of hormone. Nothing else does. This is why iodine deficiency takes a long time to manifest, why antithyroid drugs take weeks to work (they block synthesis, and the existing colloid must be used up first), and why the thyroid can be surprisingly resilient.

T4 is not the active hormone. The thyroid secretes about 90% T4 and 10% T3, but T3 is what binds the nuclear receptor. The conversion happens in peripheral tissues, chiefly liver and kidney, by removing one iodine. This puts a second control point outside the gland entirely: the body can regulate its own thyroid action by adjusting how much T4 it converts to active T3 versus inactive reverse T3. In serious illness, starvation, and after major surgery, conversion shifts toward reverse T3 — the metabolic rate falls, which is presumably adaptive. The resulting laboratory pattern of low T3 with a normal TSH is called euthyroid sick syndrome, and treating it with thyroid hormone does not help, because it is a regulated response and not a failure.

Iodine is a required substrate, not a regulator. Without dietary iodine no hormone can be made, and TSH rises without limit trying to force production. The follicles hypertrophy under constant TSH drive and the gland enlarges into an endemic goiter — a large thyroid in a hypothyroid patient, which sounds contradictory until you see that the size is TSH's doing, not the hormone's. Iodized salt, introduced in the 1920s, is one of the most cost-effective public health interventions ever undertaken.

What thyroid hormone does

T3 binds nuclear receptors in essentially every cell in the body except the adult brain, spleen, and testis. Its effects are broad because it is doing one general thing: setting the basal metabolic rate.

  • Increases basal metabolic rate by up to 60–100%, largely by increasing the number and activity of Na⁺/K⁺-ATPase pumps. Running those pumps consumes ATP, and burning ATP releases heat — the calorigenic effect. Thyroid hormone is a principal determinant of body temperature.
  • Increases glucose absorption, glycogenolysis, gluconeogenesis, lipolysis, and both protein synthesis and protein breakdown. It accelerates turnover in both directions.
  • Cardiovascular: up-regulates beta-1 adrenergic receptors on cardiac muscle. This is permissiveness (§16.2) and it is why hyperthyroid patients have tachycardia, palpitations, and a wide pulse pressure that resemble catecholamine excess despite normal catecholamine levels — and why a beta-blocker relieves those symptoms within hours while the underlying problem takes weeks to treat.
  • Nervous system: absolutely required for normal myelination and neuronal development before and shortly after birth. In adults it maintains normal alertness, mood, and reflex speed.
  • Growth and bone: required, alongside GH, for normal skeletal growth and maturation.

The HPT axis

Hypothalamic TRH → pituitary TSH → thyroid T4 and T3 → negative feedback onto pituitary thyrotrophs (dominant) and hypothalamus. The feedback is exquisitely sensitive: TSH varies logarithmically with free T4, so a small fall in free T4 produces a large rise in TSH. That property makes TSH the most sensitive single screening test for thyroid disease, and the reason it is what gets ordered first.

Clinical Connection · Graves and Hashimoto — Two Antibodies, Opposite Diseases

The two commonest thyroid diseases in iodine-replete countries are both autoimmune, and they are near-perfect mirror images. Comparing them teaches the axis.

Graves disease Hashimoto thyroiditis
Mechanism IgG antibody that binds and activates the TSH receptor Antibodies plus cytotoxic T cells that destroy follicular cells
Thyroid hormone High Low
TSH Suppressed — undetectable High
Why The gland is being driven by an antibody the feedback loop cannot see or switch off The pituitary is correctly shouting at a gland that cannot answer
Gland Diffusely enlarged, hypervascular, a bruit may be audible Firm, rubbery, enlarged early; atrophic late
Metabolic rate Up: weight loss despite increased appetite, heat intolerance, sweating Down: weight gain, cold intolerance, dry skin
Cardiac Tachycardia, atrial fibrillation, palpitations Bradycardia, low voltage on ECG
Neuromuscular Tremor, anxiety, insomnia, brisk reflexes, proximal weakness Slowed thought, depression, delayed reflex relaxation
Gut Frequent stools Constipation
Distinctive Exophthalmos and pretibial myxedema — antibody cross-reaction with orbital and dermal fibroblasts, not a hormone effect Myxedema — accumulation of hyaluronic acid in the dermis producing non-pitting swelling

Two lessons. First, the TSH tells you where the lesion is — suppressed TSH with high hormone means the gland is being driven from outside the axis; high TSH with low hormone means the gland has failed. This is the §16.10 principle in its cleanest form.

Second, the eye findings of Graves are not caused by thyroid hormone. They are caused by the antibody itself binding TSH receptors expressed on fibroblasts behind the eye, which then proliferate and secrete glycosaminoglycans that swell the orbital contents and push the globe forward. That is why exophthalmos does not resolve when the hormone level is corrected — a critically important point for patients, and a reminder that a disease's features do not all share one mechanism.

Development · Why Every Newborn's Heel Is Pricked

Thyroid hormone is required for the final stages of brain development: neuronal migration, dendritic arborization, synaptogenesis, and myelination, occurring during the third trimester and the first two to three years of life. A fetus is partly protected by maternal T4 crossing the placenta, but after birth that supply ends.

Congenital hypothyroidism — from thyroid agenesis, an enzyme defect, or severe maternal iodine deficiency — affects roughly 1 in 2,000 to 1 in 4,000 newborns. Untreated, it produces irreversible intellectual disability along with short stature, delayed dentition, and umbilical hernia. The historical name for the severe form is cretinism, a term now abandoned.

The critical feature is that the affected newborn looks normal. Maternal hormone has carried the baby through gestation, and the clinical signs — prolonged jaundice, poor feeding, hypotonia, a large tongue, constipation — appear over weeks to months, by which time irreversible damage has begun. There is no way to identify these infants by examination in the first days of life.

So they are identified by chemistry. Newborn screening measures TSH, T4, or both on a few drops of blood dried on filter paper from a heel prick, taken at 24 to 72 hours of age. Treatment is oral levothyroxine, started ideally within the first two weeks. With early treatment, cognitive outcome is normal. Screening for congenital hypothyroidism is, by most estimates, the single most cost-effective screening program in medicine, and it exists because of a developmental deadline that cannot be extended.

Imaging · Ultrasound versus Uptake — Structure and Function Asked Separately

Two thyroid studies answer two different questions, and choosing between them is a good exercise in matching modality to question.

Ultrasound answers what is the structure? High-frequency sound reflects at tissue interfaces; the thyroid is superficial, has no overlying bone or air, and is therefore an ideal ultrasound target. It shows gland size, whether a nodule is cystic or solid, its margins, whether it contains microcalcifications, and whether cervical lymph nodes are abnormal. It uses no radiation, costs little, and is done at the bedside — and it can guide a fine needle into a nodule for biopsy in real time. It cannot tell you whether the gland is working.

Radioactive iodine uptake and scan answers what is the function, and where? The patient swallows a tracer dose of iodine-123, which the sodium–iodide symporter traps exactly as it traps dietary iodide (step ① of Figure 16.4), and a gamma camera maps where it went. This images physiology, not anatomy.

The reasoning it enables is elegant. A patient has a suppressed TSH and high hormone — but why?

  • Diffusely increased uptake across the whole gland: the whole gland is being driven. Graves disease.
  • A single focus of high uptake with the rest of the gland dark: one autonomous nodule is making hormone, and the suppressed TSH has switched off all the normal tissue around it. A toxic adenoma — a "hot" nodule.
  • Near-zero uptake in a patient with high hormone: the gland is not making anything. The hormone in the blood is either leaking from a damaged gland (thyroiditis) or was swallowed.

Three different diseases, three different treatments, distinguished by a picture of where iodine went.

Calcitonin

The parafollicular C cells secrete calcitonin when blood calcium rises. It inhibits osteoclast activity, reducing bone resorption, and increases urinary calcium excretion — the functional opposite of parathyroid hormone.

Be honest about its importance in adult humans: it is minor. Total thyroidectomy removes all calcitonin and causes no calcium disorder; medullary thyroid carcinoma produces enormous calcitonin excess and causes no calcium disorder either. Calcitonin appears to matter more in childhood skeletal growth, and in pregnancy and lactation, where it may protect the maternal skeleton against the calcium drain. Its main clinical use is as a tumor marker for medullary carcinoma and as a pharmacological agent in hypercalcemia of malignancy, where supraphysiological doses do lower calcium for a few days.

Check Your Understanding 16.5

  1. Methimazole blocks thyroid peroxidase. A patient with Graves disease starts it today. Predict how long until symptoms improve, and explain using the histology.
  2. A patient has a low free T4. Her TSH is 0.3 mU/L (normal 0.4–4.0). Where is the lesion, and why is her TSH not high?
  3. Why does hyperthyroidism produce symptoms that look like sympathetic overactivity even though epinephrine and norepinephrine levels are normal or low?
Show answers
  1. Weeks — typically 4 to 8. Methimazole blocks the synthesis of new hormone at steps ④ and ⑤, but the follicle lumens contain a two- to three-month store of already-iodinated thyroglobulin, and TSH-independent release from that store continues. The drug cannot empty a tank it has only stopped filling. This is why a beta-blocker is given at the same time: it does nothing to the thyroid but blocks the up-regulated beta-1 receptors, relieving tachycardia, tremor, and anxiety within hours while the antithyroid drug works.
  2. The lesion is central — in the pituitary or hypothalamus (secondary or tertiary hypothyroidism). Her TSH is not high because the pituitary is the broken component: a healthy pituitary facing a free T4 that low would be producing a TSH of 20 or more. A TSH that is merely "normal" or slightly low in the face of clear hormone deficiency is inappropriately normal, and recognizing inappropriate normality is one of the central skills of endocrine interpretation (§16.10).
  3. Because thyroid hormone up-regulates beta-1 adrenergic receptors on cardiac and other tissue. The catecholamine signal is unchanged, but the number of receptors reading it has increased, so the response to any given signal is amplified. This is receptor regulation in the opposite direction from Amara's insulin resistance — same principle, opposite sign — and it explains why blocking the receptor works so well as symptomatic treatment.

16.6 The Parathyroid Glands and Calcium Homeostasis

Four small glands, each roughly the size of a grain of rice and together weighing about 130 mg, sit on the posterior surface of the thyroid. They are the smallest endocrine organs in the body and among the least dispensable, because plasma calcium is the most tightly defended ion in the body after potassium.

Why is calcium defended so fiercely? Because free ionized calcium sets the excitability of every excitable membrane. Extracellular Ca²⁺ binds to the outer surface of voltage-gated sodium channels and raises the threshold for opening them. Lower the calcium and you lower the threshold — nerves and muscles fire spontaneously. Raise the calcium and you raise the threshold — nerves and muscles become sluggish. Calcium is also the intracellular trigger for muscle contraction, neurotransmitter release, and a large fraction of enzyme regulation, and it is a required cofactor in the clotting cascade (Chapter 17).

Normal total plasma calcium is 8.5–10.5 mg/dL (2.1–2.6 mmol/L), of which roughly 45% is ionized and physiologically active, 40% is bound to albumin, and 15% is complexed with anions. Because so much is albumin-bound, a low albumin lowers total calcium without lowering the ionized fraction — the same free-versus-bound trap as thyroxine in §16.2, and the reason laboratories report a corrected calcium.

Parathyroid hormone: one hormone, three organs

Chief cells in the parathyroid glands carry a calcium-sensing receptor on their surface — a rare example of a receptor for an ion rather than a hormone. When ionized calcium falls, the receptor is less occupied, and PTH secretion rises within seconds. This is a humoral stimulus in its purest form.

PTH raises blood calcium by three routes:

1 · Bone — mobilize the reservoir. PTH binds receptors on osteoblasts (not osteoclasts, which have no PTH receptor), causing them to express RANK ligand, which binds RANK on osteoclast precursors and drives their maturation and activity. Osteoclasts then dissolve mineralized matrix, releasing calcium and phosphate into blood. Bone holds about 99% of body calcium — roughly 1 kg — so the reservoir is effectively unlimited (Chapter 6). Note the indirect route: PTH cannot talk to an osteoclast; it must speak through an osteoblast. That detail is why drugs targeting RANK ligand work.

2 · Kidney — keep what you have, and dump phosphate. PTH increases calcium reabsorption in the distal convoluted tubule, and simultaneously decreases phosphate reabsorption in the proximal tubule, causing phosphaturia. That second action matters more than it looks. Bone resorption releases calcium and phosphate together, and if phosphate rose alongside calcium the two would precipitate as calcium phosphate in soft tissue. By excreting phosphate at the same time, PTH ensures that the calcium it liberates stays in solution.

3 · Intestine — indirectly, via vitamin D. PTH stimulates the renal enzyme 1α-hydroxylase, which converts 25-hydroxyvitamin D into calcitriol (1,25-dihydroxy­ vitamin D), the active hormone. Calcitriol acts on intestinal epithelium to increase synthesis of calcium transport proteins, raising dietary calcium absorption from a baseline of about 15% to as much as 30–40%. This is the slowest arm of the response — it requires gene transcription in two organs — but it is the only one that adds new calcium to the body rather than moving existing calcium around.

Clinical Connection · Tetany After Thyroid Surgery

The parathyroid glands are tiny, tan-brown, and sit on the back of the thyroid, sometimes embedded in it. A surgeon removing a thyroid must find and preserve four structures the size of grains of rice, in a bloody field, without damaging their delicate blood supply.

When that fails, the patient develops acute hypoparathyroidism, and the presentation is a direct readout of what calcium does to membranes. Within 24–72 hours:

  • Perioral and fingertip paresthesias — tingling around the mouth and in the fingertips, usually the first symptom, because sensory nerves fire spontaneously as their threshold falls.
  • Carpopedal spasm — sustained involuntary contraction of the hand into a characteristic posture, with the wrist and metacarpophalangeal joints flexed and the fingers extended.
  • Chvostek sign — tapping over the facial nerve just anterior to the ear produces twitching of the ipsilateral facial muscles. A motor nerve so close to threshold that a mechanical tap fires it.
  • Trousseau sign — inflating a blood pressure cuff above systolic pressure for three minutes induces carpal spasm, because local ischemia and alkalosis further reduce ionized calcium.
  • Laryngospasm and seizures in severe cases; prolongation of the QT interval on the ECG, because the cardiac action potential's plateau phase is carried by calcium current (Chapter 18).

Every one of these follows from a single sentence of physiology: low extracellular calcium lowers the threshold of voltage-gated sodium channels, so excitable tissue fires spontaneously. You do not memorize the list. You derive it.

Treatment is calcium — intravenously if there is spasm, orally with calcitriol for maintenance, and note why calcitriol rather than plain vitamin D: without PTH there is no 1α-hydroxylase stimulation, so the patient cannot activate ordinary vitamin D. You must give the finished hormone. Understanding the pathway tells you which drug to choose.

Thread 1 · Structure Determines Function

Calcium homeostasis is a story about a bank. The skeleton contains a kilogram of calcium locked into hydroxyapatite crystals; the entire extracellular fluid contains about a gram. The ratio is a thousand to one.

That structural fact makes the whole system possible. A variable defended within ±0.5 mg/dL over decades needs a reservoir so large that withdrawals do not perceptibly deplete it — and bone is that reservoir. The design cost is equally structural: chronic withdrawals do, eventually, deplete the bank, and the account is the skeleton itself. Chronic hyperparathyroidism produces osteitis fibrosa cystica, with cystic bone lesions and fractures; chronic kidney disease produces sustained secondary hyperparathyroidism and renal osteodystrophy. Adwoa Mensah's osteoporosis (Chapter 6) is partly the sum of forty years of small withdrawals.

The body is willing to trade the strength of its skeleton for the excitability of its nerves, because a fracture is survivable and a cardiac arrhythmia is not. Homeostasis has priorities, and it enforces them structurally.

Aging · The Calcium Economy at 25, 45, and 78

Follow one variable across three of our four family members.

Nia, 24. Peak bone mass is reached in the late twenties. Intestinal calcium absorption is efficient, renal 1α-hydroxylase is abundant, estrogen restrains osteoclasts, and mechanical loading from running continuously signals osteocytes to maintain mineral. Net calcium balance is neutral to positive.

Amara, 45. Perimenopausal. Estrogen is beginning to fluctuate and fall, and estrogen's main skeletal action is to restrain osteoclasts and promote osteoblast survival — so as it falls, resorption accelerates. Bone loss of roughly 0.5–1% per year begins, and will briefly reach 2–3% per year in the five years around menopause (Chapter 27). Her vitamin D is likely low: she works nights, spends daylight asleep indoors, and cutaneous synthesis needs sunlight.

Adwoa, 78. Three age-related changes compound. Cutaneous vitamin D synthesis at 78 is roughly a quarter of what it was at 20 for the same sun exposure, because epidermal 7-dehydrocholesterol declines. Renal 1α-hydroxylase activity falls with declining GFR, so less calcitriol is produced from what precursor there is. Intestinal responsiveness to calcitriol itself declines — receptor down-regulation again. The consequence is a chronically low-normal calcium absorption, chronically elevated PTH (secondary hyperparathyroidism of aging), and a slow, silent, decades-long transfer of mineral from skeleton to plasma. Her osteoporosis is not a disease of bone alone. It is a disease of the skin, the kidney, and the gut, expressed in bone.

Check Your Understanding 16.6

  1. A patient with chronic kidney disease has a low calcium, a high phosphate, and a PTH of 340 pg/mL (normal 15–65). Is this primary or secondary hyperparathyroidism, and what is the initiating event?
  2. Why does hyperventilating during a panic attack sometimes produce tingling in the fingers and around the mouth, when total plasma calcium has not changed?
Show answers
  1. Secondary. In primary hyperparathyroidism the gland itself is autonomous, so calcium is high. Here calcium is low, meaning the glands are responding correctly to a genuine stimulus. The initiating events are renal: the failing kidney cannot make enough 1α-hydroxylase to produce calcitriol, so intestinal calcium absorption falls; and it cannot excrete phosphate, so phosphate rises and complexes ionized calcium, lowering it further. Low calcium drives PTH up appropriately and continuously. The bone pays. This is the cardiorenal-skeletal link that returns in Chapter 26, and it is one reason Amara's drifting creatinine matters more than it appears to.
  2. Because hyperventilation blows off CO₂ and raises blood pH — respiratory alkalosis (Chapter 31). Albumin's negatively charged binding sites release hydrogen ions as pH rises, which frees those sites to bind calcium instead. More calcium becomes protein-bound, so the ionized fraction falls even though the total is unchanged. Ionized calcium is the physiologically active fraction, so nerve thresholds drop and paresthesias appear. It is a perfect demonstration that total concentration is not the regulated variable — free concentration is.

16.7 The Adrenal Glands and the RAAS

Two adrenal glands sit like caps on the superior pole of each kidney (ad- + renal, "upon the kidney"), each weighing 4–5 g. Like the pituitary, each is two organs in one capsule, of two embryonic origins, doing two unrelated jobs.

Histology · Reading the Adrenal Cortex by Its Layers

A section through an adrenal gland shows an outer cortex (about 80–90% of the mass, yellowish from stored cholesterol) and an inner medulla (dark red-brown). The cortex is mesodermal; the medulla is neural crest. The cortex is arranged in three concentric zones, and the zone's architecture predicts its product.

Zone Position Cell arrangement Product Chief regulator
Zona glomerulosa Outermost, just under the capsule Tight round clusters (glomus, a ball) Mineralocorticoids — aldosterone Angiotensin II; plasma K⁺
Zona fasciculata Middle, thickest Long straight cords (fascis, a bundle) between radial capillaries; foamy cytoplasm packed with lipid droplets — the spongiocytes Glucocorticoids — cortisol ACTH
Zona reticularis Innermost, adjacent to medulla A branching net (reticulum) Adrenal androgens — DHEA, androstenedione ACTH
Medulla Center Large chromaffin cells in clusters around venous sinuses; stain brown with chromium salts Epinephrine (~80%), norepinephrine (~20%) Preganglionic sympathetic fibers

The mnemonic GFR — Salt, Sugar, Sex works and is worth having: Glomerulosa, Fasciculata, Reticularis making salt (aldosterone), sugar (cortisol), and sex (androgens), with the deeper you go, the sweeter it gets.

Two structural observations that pay off. First, only the glomerulosa expresses aldosterone synthase, and only the fasciculata and reticularis express 17α-hydroxylase — which is why one gland can make two steroids that do completely different things from the same cholesterol starting material. The enzyme complement, not the substrate, sets the product. Second, the foamy cytoplasm of the fasciculata is stored cholesterol esters: steroid hormones are not stored as hormone (§16.2), so the cell stores the raw material instead and can begin synthesis within minutes of an ACTH signal.

The adrenal medulla: a sympathetic ganglion that lost its axons

Chromaffin cells are modified postganglionic sympathetic neurons. They receive preganglionic cholinergic input directly from the sympathetic chain, and when stimulated they release epinephrine (about 80%) and norepinephrine (about 20%) into the blood.

This is why the fight-or-flight response has two phases. Direct sympathetic innervation acts in milliseconds and stops the instant firing stops. Adrenal catecholamines take 20–30 seconds to arrive but persist for 5–10 times longer than a nerve signal because they must be cleared from the whole circulation. The medulla is the sympathetic nervous system's way of sustaining an emergency, and it reaches tissues — like adipose tissue and much of the liver — that are sparsely innervated. Effects: heart rate and contractility up, bronchodilation, glycogenolysis and lipolysis, blood shunted from gut and skin to muscle, pupils dilated, alertness heightened.

Clinical Connection · Pheochromocytoma — Hypertension That Comes in Waves

A pheochromocytoma is a tumor of chromaffin cells that secretes catecholamines outside all neural control. It is rare — perhaps 0.2–0.6% of hypertensive patients — but it is one of the few surgically curable causes of hypertension, and its presentation is a pure demonstration of what catecholamines do.

The classic triad is episodic headache, sweating, and palpitations, occurring in paroxysms that last minutes to an hour, on a background of hypertension that is often severe and sometimes only intermittent. Patients describe a sense of impending doom — which is precisely what a bolus of adrenaline feels like. Attacks may be provoked by abdominal palpation, anesthesia induction, or certain drugs.

The episodic pattern is the key insight, and it follows from §16.1: an endocrine signal is concentration-coded, so a tumor releasing catecholamines in bursts produces symptoms in bursts, unlike essential hypertension, which is a continuous elevated pressure with no symptoms at all. Diagnosis is by measuring plasma or urinary metanephrines — the breakdown products, which are produced continuously inside the tumor and therefore do not miss the gaps between bursts. That is a lovely piece of reasoning: when the hormone is intermittent, measure the metabolite.

One point of practical physiology. Before surgery, the patient must be blocked with an alpha-adrenergic antagonist first, and only then a beta-blocker. Give a beta-blocker alone and you remove beta-2-mediated vasodilation while leaving alpha-1 vasoconstriction unopposed — blood pressure rises catastrophically. Sequence matters because two receptor subtypes with opposite vascular effects are being driven by one molecule (§16.2).

Aldosterone and the renin–angiotensin–aldosterone system

Now the loop that this book has been building toward. Read this section twice. It is the single most integrative mechanism in human physiology, connecting the kidney, the liver, the lung, the adrenal gland, the arterioles, the heart, and the brain into one circuit, and it will reappear in Chapters 18, 19, 26, and 31.

The problem the RAAS solves is this: the body must defend arterial blood pressure, and blood pressure depends on blood volume, and blood volume depends on total body sodium. Wherever sodium goes, water follows osmotically. Control sodium and you control volume; control volume and you control pressure. The kidney is where sodium is kept or lost, so the kidney must be both the sensor and the effector.

                THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

  ┌────────────────── THREE STIMULI, ALL SENSED BY THE KIDNEY ───────────────┐
  │ ① Fall in renal perfusion pressure, sensed by stretch-sensitive          │
  │   granular cells in the AFFERENT ARTERIOLE wall (a baroreceptor)          │
  │ ② Fall in NaCl delivery to the MACULA DENSA of the distal tubule          │
  │ ③ Direct SYMPATHETIC stimulation of granular cells via β1 receptors       │
  └───────────────────────────────┬──────────────────────────────────────────┘
                                  ▼
              KIDNEY · juxtaglomerular (granular) cells secrete
              ╔══════════════════════════════════════════════╗
              ║   R E N I N     (an enzyme, not a hormone)   ║
              ╚═══════════════════════╤══════════════════════╝
                                      │ cleaves
  LIVER continuously makes            ▼
  ANGIOTENSINOGEN ──────────►  ANGIOTENSIN I  (10 aa, inactive)
  (an always-available                │
   circulating substrate)             │ ANGIOTENSIN-CONVERTING ENZYME (ACE)
                                      │ on LUNG capillary endothelium
                                      │   ◄── blocked by ACE INHIBITORS
                                      ▼        (-pril drugs)
              ╔═══════════════════════════════════════════════╗
              ║   A N G I O T E N S I N   I I   (8 aa)        ║
              ║   the active hormone — acts at AT1 receptors  ║
              ║   ◄── blocked by ARBs (-sartan drugs)         ║
              ╚═══╤════════╤═════════╤═════════╤══════════╤═══╝
                  │        │         │         │          │
        ┌─────────┘   ┌────┘    ┌────┘    ┌────┘     ┌────┘
        ▼             ▼         ▼         ▼          ▼
  ┌───────────┐ ┌──────────┐ ┌────────┐ ┌────────┐ ┌────────────┐
  │ ARTERIOLES│ │ ADRENAL  │ │ KIDNEY │ │ BRAIN  │ │ PITUITARY  │
  │ potent    │ │ CORTEX   │ │ prox.  │ │ hypo-  │ │ posterior  │
  │ VASO-     │ │ zona     │ │ tubule │ │ thal.  │ │ lobe       │
  │ CONSTRIC- │ │ glomer-  │ │ Na⁺    │ │ THIRST │ │ releases   │
  │ TION      │ │ ulosa    │ │ reabs. │ │ + salt │ │ ADH        │
  │           │ │ makes    │ │ direct │ │ craving│ │            │
  │ ↑ TPR     │ │ ALDO-    │ │        │ │        │ │ ↑ H₂O      │
  │           │ │ STERONE  │ │        │ │ ↑ H₂O  │ │ reabs.     │
  └─────┬─────┘ └────┬─────┘ └───┬────┘ │ intake │ └─────┬──────┘
        │            │           │      └───┬────┘       │
        │            ▼           │          │            │
        │  ┌──────────────────┐  │          │            │
        │  │ COLLECTING DUCT  │  │          │            │
        │  │ principal cells  │  │          │            │
        │  │ ↑ ENaC channels  │  │          │            │
        │  │ ↑ Na⁺/K⁺ ATPase  │  │          │            │
        │  │ (gene activation │  │          │            │
        │  │  — takes hours)  │  │          │            │
        │  │ RETAIN Na⁺ + H₂O │  │          │            │
        │  │ EXCRETE K⁺ + H⁺  │  │          │            │
        │  │ ◄── blocked by   │  │          │            │
        │  │  SPIRONOLACTONE  │  │          │            │
        │  └────────┬─────────┘  │          │            │
        │           │            │          │            │
        └───────────┴────────────┴──────────┴────────────┘
                                 ▼
                    ╔═════════════════════════════╗
                    ║  ↑ BLOOD VOLUME             ║
                    ║  ↑ TOTAL PERIPHERAL RESIST. ║
                    ║  = ↑ ARTERIAL PRESSURE      ║
                    ╚══════════════╤══════════════╝
                                   │
        NEGATIVE FEEDBACK ─────────┘
        Restored renal perfusion switches renin secretion OFF.

  FOURTH, SLOW ARM — long-term structural damage:
  Angiotensin II and aldosterone are also GROWTH FACTORS.  Sustained,
  they drive cardiac myocyte hypertrophy, fibroblast proliferation and
  COLLAGEN deposition in myocardium and vessel wall, and glomerular
  sclerosis.  This is "remodelling," and it is why ACE inhibitors improve
  survival in heart failure far beyond what their pressure effect predicts.

Figure 16.5 — The renin–angiotensin–aldosterone system, from renal stimulus to arterial pressure, with the sites of drug action.

Described: A cascade beginning at the kidney. Three stimuli trigger it: a fall in renal perfusion pressure sensed by stretch-sensitive granular cells in the afferent arteriole wall; a fall in sodium chloride delivery to the macula densa of the distal tubule; and direct sympathetic stimulation of granular cells through beta-1 receptors. In response, the juxtaglomerular granular cells secrete renin, which is an enzyme rather than a hormone. Renin cleaves angiotensinogen, a substrate the liver produces continuously, into the inactive ten-amino-acid peptide angiotensin I. Angiotensin-converting enzyme, located mainly on lung capillary endothelium, removes two more amino acids to make the eight-amino-acid active hormone angiotensin II; ACE inhibitors block this step and angiotensin receptor blockers block the receptor downstream. Angiotensin II then acts at five sites. On arterioles it is a potent vasoconstrictor, raising total peripheral resistance. On the adrenal zona glomerulosa it stimulates aldosterone synthesis. On the renal proximal tubule it directly increases sodium reabsorption. On the hypothalamus it produces thirst and salt craving, increasing water intake. On the posterior pituitary it triggers ADH release, increasing renal water reabsorption. Aldosterone in turn acts on principal cells of the collecting duct, where by direct gene activation over several hours it increases the number of epithelial sodium channels and sodium-potassium ATPase pumps, so that sodium and water are retained while potassium and hydrogen ions are excreted; spironolactone blocks this receptor. All arms converge on increased blood volume and increased peripheral resistance, and therefore increased arterial pressure, which restores renal perfusion and switches renin secretion off — the negative feedback that closes the loop. A final note describes a fourth, slow arm: angiotensin II and aldosterone also act as growth factors, driving cardiac myocyte hypertrophy, fibroblast proliferation and collagen deposition in myocardium and vessel wall, and glomerular sclerosis. This structural remodelling explains why ACE inhibitors improve survival in heart failure by more than their blood-pressure effect alone would predict.

Several features of this system deserve to be stated explicitly.

Renin is an enzyme, not a hormone. It has no receptor and no target cell. It performs one proteolytic cleavage on one substrate. Because angiotensinogen is always present in excess, renin secretion is the rate-limiting step for the entire cascade — which is why plasma renin activity is the number that gets measured.

Angiotensin II raises pressure by four independent routes. Vasoconstriction raises resistance immediately, within seconds to minutes. Direct proximal tubular sodium reabsorption raises volume over minutes to hours. Aldosterone raises volume over hours to days — it is a steroid, so it must transcribe genes, and its onset is correspondingly slow. Thirst and ADH raise volume over hours. A system with four effectors on different timescales can defend pressure against both an acute hemorrhage and a chronic low-salt diet, using the same signal.

Aldosterone trades sodium for potassium and hydrogen. In the collecting duct principal cell, aldosterone increases apical ENaC channels and basolateral Na⁺/K⁺-ATPase. Sodium reabsorption makes the tubular lumen electrically negative, and that negativity drives potassium secretion by principal cells and hydrogen secretion by adjacent intercalated cells. So every aldosterone effect comes in a set: sodium and water in, potassium and acid out. This is why hyperaldosteronism produces hypertension with hypokalemia and metabolic alkalosis, and why Amara will develop exactly that pattern from a diuretic in Chapter 31.

Potassium regulates aldosterone directly. The zona glomerulosa senses plasma K⁺ itself, so a rising potassium stimulates aldosterone, which excretes potassium. That is a complete feedback loop that does not involve renin at all — which is why aldosterone serves as both a volume hormone and a potassium hormone, and why it can be pulled in two directions at once.

Thread 2 · Homeostasis Is the Master Concept

The RAAS is a beautifully designed loop that becomes a disease when the input it is reading is wrong.

The kidney does not measure blood volume or blood pressure. It measures its own perfusion, and it assumes that low renal perfusion means low systemic volume. In hemorrhage that assumption is correct and the RAAS is life-saving.

In heart failure, the assumption is false. Cardiac output is low because the pump is weak, not because volume is low, so renal perfusion falls while the circulation is already overfilled. The kidney reads it as hemorrhage. It retains salt and water, raising preload on a ventricle that cannot handle the preload it already has, and constricts arterioles, raising the afterload the same failing ventricle must eject against. Volume rises, congestion worsens, cardiac output falls further, renal perfusion falls further, and renin rises further. A negative feedback loop, reading a variable that has become uncoupled from the thing it stands for, has turned into a positive one.

This is the cardiorenal syndrome, and it is why the drugs that improve survival in heart failure — ACE inhibitors, angiotensin receptor blockers, and mineralocorticoid antagonists — all work by interrupting a normal homeostatic response. Occasionally the correct treatment is to switch off a loop that is defending the wrong thing. Amara's elevated renin and elevated aldosterone, in a woman with a high blood pressure and a failing ventricle, is this loop being caught in the act.

Cortisol and the stress response

The zona fasciculata makes roughly 15–25 mg of cortisol per day under ACTH control, with a pronounced circadian rhythm: a peak just before waking (typically 06:00–08:00), a steady decline through the day, and a nadir around midnight that should be nearly undetectable. That rhythm is generated by the hypothalamic suprachiasmatic nucleus and entrained by light (Chapter 12, and §16.9 below). Cortisol is the body's principal glucocorticoid, and the name tells you its first job.

Metabolic actions — cortisol is a fuel-mobilizing, insulin-opposing hormone.

  • Gluconeogenesis in the liver is increased: cortisol induces the enzymes that build glucose from amino acids and glycerol.
  • Protein catabolism in skeletal muscle supplies those amino acids. Chronically this produces the thin limbs of Cushing syndrome.
  • Lipolysis in peripheral adipose tissue releases fatty acids — while, paradoxically, promoting fat deposition centrally in the abdomen, face, and upper back. The mechanism involves regional differences in receptor density and in the enzyme 11β-hydroxysteroid dehydrogenase type 1, which regenerates active cortisol locally within visceral fat.
  • Peripheral insulin resistance is induced directly: cortisol reduces GLUT4 translocation in muscle and fat. Cortisol is a counter-regulatory hormone, and this is the mechanism that connects Amara's shift work to her glucose.

Cardiovascular actions — permissiveness again. Cortisol maintains the expression and coupling of adrenergic receptors on vascular smooth muscle. Without it, vessels do not respond properly to norepinephrine, and vascular tone collapses. This is why adrenal insufficiency causes refractory hypotension, and why cortisol is essential for surviving any physiological stress at all. At high concentrations cortisol also binds mineralocorticoid receptors, contributing sodium retention and potassium loss.

Anti-inflammatory and immunosuppressive actions. Cortisol inhibits phospholipase A2 (cutting off prostaglandin and leukotriene synthesis at its source), suppresses cytokine transcription, stabilizes lysosomes, reduces capillary permeability, and causes lymphocytes and eosinophils to leave the circulation while neutrophils are released from marrow — producing the characteristic blood picture of neutrophilia with lymphopenia (Chapter 17). At physiological levels this restrains inflammation from overshooting; at pharmacological levels it is the basis of an entire class of drugs.

The general adaptation syndrome. Hans Selye's three-stage model of the response to any sustained stressor remains the best framework for what cortisol is for.

Stage Timescale Dominant mediators What happens
1 · Alarm Seconds to minutes Sympathetic nerves, then adrenal catecholamines Fight-or-flight: heart rate, blood pressure, glucose, and alertness rise; digestion and reproduction are deferred
2 · Resistance Hours to weeks Cortisol, GH, glucagon, ADH, aldosterone Sustained fuel mobilization: gluconeogenesis, protein catabolism, salt and water retention. The body holds a new, expensive steady state
3 · Exhaustion Weeks to years Continued cortisol; loss of adaptation The costs come due: immune suppression, muscle wasting, visceral obesity, insulin resistance, hypertension, bone loss, impaired wound healing, hippocampal atrophy

Stage 3 is the one that matters for this book. Nothing in the stress response is designed for permanence. Cortisol's actions are excellent for an afternoon and destructive for a decade, and essentially every one of the stage-3 costs is on Amara's problem list.

Clinical Connection · Cushing versus Addison — Reading Cortisol in Both Directions

Cushing syndrome (excess) Addison disease (deficiency)
Commonest cause Exogenous glucocorticoid therapy. Endogenous: pituitary ACTH adenoma (Cushing disease), adrenal tumor, ectopic ACTH Autoimmune destruction of the adrenal cortex (~80% in high-income countries); tuberculosis worldwide
Body habitus Central obesity, "moon face," dorsocervical fat pad, thin arms and legs from protein catabolism Weight loss, anorexia, fatigue
Skin Thin, easily bruised; wide purple striae where dermal collagen has failed under stretch Hyperpigmentation of skin creases, scars, and buccal mucosa
Blood pressure High Low, with orthostatic dizziness
Glucose High — steroid diabetes Low, with fasting hypoglycemia
Sodium / potassium Na⁺ high, K⁺ low Na⁺ low, K⁺ high
Bone Osteoporosis, fractures Usually normal
Immune Suppressed; infections; poor healing Normal, but crisis under stress
Emergency form — Adrenal crisis: shock, hypoglycemia, vomiting, death

Two features are worth deriving rather than memorizing.

Why is the skin dark in Addison disease? Because cortisol is low, negative feedback is removed and the pituitary produces enormous quantities of ACTH. ACTH is cleaved from a large precursor, pro-opiomelanocortin (POMC), and shares its amino-terminal sequence with melanocyte-stimulating hormone; at high concentrations ACTH itself stimulates melanocortin-1 receptors on melanocytes. Hyperpigmentation is therefore a marker of high ACTH, which localizes the lesion to the adrenal gland — primary adrenal failure. A patient with secondary adrenal insufficiency, from pituitary failure, has low ACTH and is pale. One glance at the buccal mucosa distinguishes two diseases with identical cortisol levels.

Why are the limbs thin while the trunk is fat? Because cortisol does two different things in two fat and muscle compartments: it catabolizes peripheral protein and mobilizes peripheral fat while promoting central fat deposition. The physical examination is a map of regional receptor biology.

Check Your Understanding 16.7

  1. A patient is started on an ACE inhibitor for hypertension. Predict the effect on plasma renin, angiotensin II, aldosterone, and potassium, and explain each.
  2. Why does a patient with an aldosterone-secreting adrenal adenoma have hypertension and hypokalemia but not progressive edema and massive weight gain?
  3. Amara's renin is high and her aldosterone is high. Which one is driving which, and what would you expect if the primary problem were an aldosterone-producing tumor instead?
Show answers
  1. Angiotensin II falls, because its production is blocked. Aldosterone falls, because angiotensin II is its dominant stimulus — so potassium rises (a well-known and occasionally dangerous effect of these drugs, especially in kidney disease). Renin rises, because the loss of angiotensin II removes short-loop negative feedback on the granular cells and because pressure falls; this is why plasma renin activity is uninterpretable in a patient already taking an ACE inhibitor, and why such drugs are stopped before the test.
  2. Because of aldosterone escape. Sodium retention initially expands volume, but the resulting rise in atrial stretch releases atrial natriuretic peptide (§16.9), and the rise in renal perfusion pressure causes pressure natriuresis in the proximal tubule. Both dump sodium independently of aldosterone, so volume expansion plateaus after roughly 1.5–2 kg. The escape mechanisms work on sodium; they do not rescue potassium, because the collecting duct continues to trade potassium for sodium. Hence sustained hypokalemia with only modest volume overload — a very characteristic pattern, and a good example of one homeostatic system covering part of another's failure.
  3. Renin is driving aldosterone: this is secondary hyperaldosteronism, appropriate to whatever is reducing her renal perfusion — high sympathetic tone, arteriolar disease, early renal impairment, and a heart that is not perfusing well. If the tumor were primary, the adrenal gland would be autonomous, its aldosterone would be raising volume and pressure, and the resulting high renal perfusion would suppress renin. The pattern would be high aldosterone with low renin. The aldosterone-to-renin ratio is exactly this reasoning turned into a number.

16.8 The Pancreas and Glucose Homeostasis

Histology · Islands in a Sea of Enzyme

A pancreatic section is overwhelmingly dark purple: densely packed acinar cells, pyramidal, with basophilic basal cytoplasm crowded with rough endoplasmic reticulum and apical zymogen granules full of digestive proenzymes. That is the exocrine pancreas — 98–99% of the organ.

Scattered through it, and unmistakable, are pancreatic islets (islets of Langerhans): pale, round-to-oval clusters of 100 to 1,000 cells, richly capillarized, with no duct. About one to two million of them, together weighing 1–2 g. On a routine stain they look like light patches in dark tissue — precisely the appearance of islands, which is what Paul Langerhans named them in 1869 at the age of 22 without knowing what they did.

Immunostaining separates four cell types:

Cell Share of islet Product Action
Beta (β) ~70% Insulin and C-peptide Lowers blood glucose; the only hypoglycemic hormone
Alpha (α) ~20% Glucagon Raises blood glucose
Delta (δ) ~5% Somatostatin Paracrine brake on both insulin and glucagon
PP / F ~1–2% Pancreatic polypeptide Modulates exocrine secretion and appetite

The architecture is functional, not incidental. Beta cells sit centrally and alpha cells peripherally, blood flows from core to rim, and the cells are electrically coupled — so insulin-rich blood washes over alpha cells and directly suppresses glucagon. The islet is not four cell types near each other; it is a small integrated computer, and its wiring is anatomy.

Insulin: the only hormone that lowers blood glucose

Beta cells sense glucose directly. Glucose enters through GLUT2, is phosphorylated by glucokinase — the sensor, because its kinetics match the physiological glucose range — and its metabolism raises ATP, which closes ATP-sensitive potassium channels, depolarizing the cell, opening voltage-gated calcium channels, and triggering exocytosis of pre-made insulin granules. (Sulfonylurea drugs close the same K-ATP channel pharmacologically, which is why they cause insulin release regardless of glucose, and therefore why they can cause hypoglycemia.)

Insulin binds a receptor tyrosine kinase — not a G-protein-coupled receptor. The receptor autophosphorylates, recruits insulin receptor substrate proteins, and activates the PI3-kinase pathway. The signature downstream event is translocation of GLUT4 transporters from intracellular vesicles into the plasma membrane of skeletal muscle and adipose cells. GLUT4 is the only insulin-dependent glucose transporter, and this single step accounts for most of insulin-stimulated glucose disposal.

Insulin's actions are those of a storage hormone:

Tissue Carbohydrate Fat Protein
Liver Glycogen synthesis up; gluconeogenesis and glycogenolysis off Lipogenesis and VLDL export up Protein synthesis up
Skeletal muscle GLUT4 inserted; glucose uptake and glycogen synthesis up — Amino acid uptake and protein synthesis up; breakdown down
Adipose GLUT4 inserted; glucose uptake up Lipoprotein lipase activated (fat stored); hormone-sensitive lipase inhibited (fat not released) —

Note that liver and brain do not require insulin for glucose uptake — the liver uses GLUT2 and the brain GLUT1 and GLUT3, both insulin-independent. This is why the brain keeps working in type 1 diabetes even as muscle starves, and why hypoglycemia, not hyperglycemia, is what makes a diabetic patient acutely confused.

Glucagon: the mirror image

Alpha cells sense falling glucose (and rising amino acids, and sympathetic stimulation) and secrete glucagon, which acts almost entirely on the liver through a cAMP cascade: glycogenolysis, gluconeogenesis, and — in prolonged fasting — ketogenesis. Glucagon is the first line of defense against hypoglycemia, backed by epinephrine, then cortisol and GH over hours.

              GLUCOSE HOMEOSTASIS — AN ANTAGONISTIC PAIR
                    set point ≈ 70-100 mg/dL fasting

   GLUCOSE RISES (a meal)                    GLUCOSE FALLS (fasting, exercise)
          │                                              │
          ▼                                              ▼
   ┌──────────────────┐                        ┌──────────────────┐
   │ PANCREATIC ISLET │  ← sensor AND control  │ PANCREATIC ISLET │
   │   BETA CELL      │    centre in one cell  │   ALPHA CELL     │
   └────────┬─────────┘                        └────────┬─────────┘
            │ secretes                                  │ secretes
            ▼                                           ▼
      ╔═══════════╗                              ╔═══════════╗
      ║  INSULIN  ║                              ║ GLUCAGON  ║
      ╚═════╤═════╝                              ╚═════╤═════╝
   ┌────────┼────────┐                                 │
   ▼        ▼        ▼                                 ▼
 LIVER   MUSCLE   ADIPOSE                            LIVER
 glyco-  GLUT4 →  GLUT4 →                     glycogenolysis ↑
 genesis membrane membrane                    gluconeogenesis ↑
   ↑     glucose  glucose                     ketogenesis ↑
 gluco-  uptake ↑ uptake ↑                          │
 neo-      │     fat stored                         ▼
 genesis   │     lipolysis OFF              GLUCOSE RELEASED
   OFF     │        │                       INTO BLOOD
   │       │        │                              │
   └───────┴────────┘                              │
           ▼                                       ▼
   GLUCOSE REMOVED FROM BLOOD              ┌──────────────┐
           │                               │  GLUCOSE ↑   │
           ▼                               └──────┬───────┘
   ┌──────────────┐                               │
   │  GLUCOSE ↓   │                               │
   └──────┬───────┘                               │
          │  NEGATIVE FEEDBACK                    │
          └────────────► back to set point ◄──────┘

 ══ WHERE THE LOOP BREAKS ══════════════════════════════════════════════
   TYPE 1 DIABETES              TYPE 2 DIABETES
   ┌────────────────────┐       ┌──────────────────────────────────────┐
   │ Autoimmune destruc-│       │ Beta cells intact (at first).        │
   │ tion of BETA CELLS │       │ TARGET TISSUES have DOWN-REGULATED   │
   │                    │       │ and UNCOUPLED their receptors.       │
   │ THE SIGNAL IS      │       │ THE SIGNAL IS SENT AND IGNORED.      │
   │ NEVER SENT.        │       │                                      │
   │ Insulin: LOW/ABSENT│       │ Insulin: HIGH (then eventually low   │
   │ C-peptide: absent  │       │ as exhausted beta cells fail)        │
   │ = EFFERENT SIGNAL  │       │ = EFFECTOR / TARGET FAILURE          │
   │   FAILURE          │       │                                      │
   │ Treat: replace the │       │ Treat: restore the response —        │
   │ hormone            │       │ exercise, weight loss, metformin     │
   └────────────────────┘       └──────────────────────────────────────┘
              AMARA IS THE RIGHT-HAND BOX.  Insulin 28 µU/mL.

Figure 16.6 — The glucose homeostasis loop, with insulin and glucagon as antagonists, and the two points at which diabetes breaks it.

Described: Two mirrored halves of one feedback loop around a fasting set point of roughly 70 to 100 mg/dL. On the left, a rise in glucose after a meal is sensed by the pancreatic islet beta cell, which acts as both sensor and control centre and secretes insulin. Insulin acts on three tissues: the liver, where glycogen synthesis increases and gluconeogenesis is switched off; skeletal muscle, where GLUT4 transporters move into the membrane and glucose uptake rises; and adipose tissue, where GLUT4 also inserts, fat is stored, and lipolysis is switched off. Glucose is removed from the blood, glucose falls, and the loop returns toward the set point. On the right, falling glucose during fasting or exercise is sensed by the alpha cell, which secretes glucagon; glucagon acts almost entirely on the liver, increasing glycogenolysis, gluconeogenesis, and ketogenesis, releasing glucose into the blood and raising it back to the set point. Beneath, two boxes show where the loop breaks. In type 1 diabetes, autoimmune destruction of beta cells means the signal is never sent: insulin and C-peptide are low or absent, and the failure is of the efferent signal, so treatment is to replace the hormone. In type 2 diabetes, beta cells are intact at first but the target tissues have down-regulated and uncoupled their receptors, so the signal is sent and ignored: insulin is high, and only much later falls as exhausted beta cells fail. This is an effector or target failure, and treatment aims to restore the response through exercise, weight loss, and drugs such as metformin. A final line notes that Amara, with a fasting insulin of 28 microunits per millilitre, belongs in the right-hand box.

Type 1 and type 2 are failures at different boxes

Return to the four-box architecture of §1.5 — receptor, control center, efferent signal, effector — and to the down-regulation principle of §16.2. Both diabetes types produce hyperglycemia. They are otherwise almost opposite diseases.

Type 1 Type 2
Broken box Efferent signal Effector / target
Mechanism Autoimmune T-cell destruction of beta cells Receptor down-regulation, post-receptor uncoupling, lipid-induced signaling interference
Onset Usually childhood/adolescence; abrupt, over weeks Usually adulthood; insidious, over years
Body habitus Often lean; weight loss at presentation Usually central adiposity
Plasma insulin Low to absent High early; falls late
C-peptide Absent Normal or high
Ketoacidosis Characteristic — no insulin means unrestrained lipolysis and ketogenesis Uncommon, because residual insulin suppresses lipolysis
Treatment logic Replace the missing signal — insulin, always Restore the response — exercise, weight loss, metformin, then agents that add signal

The distinction is not academic; it dictates therapy. You cannot fix a broken effector by shouting louder at it, which is why the first treatment for type 2 diabetes is not a drug that adds insulin but interventions that restore sensitivity.

Exercise & Sport · The Hormonal Response to Exercise, and the One Effect That Never Fails

During a single bout. Within seconds, sympathetic outflow and adrenal catecholamines rise — epinephrine can increase 10-fold in maximal work — mobilizing hepatic glycogen and adipose triglyceride. Glucagon rises and, crucially, insulin falls (sympathetic alpha-2 stimulation inhibits beta cells), which is exactly what is needed: falling insulin permits lipolysis and hepatic glucose output while the working muscle takes up glucose anyway. Growth hormone rises 5- to 10-fold above about 60% of VO₂max, sparing glucose and mobilizing fat. Cortisol rises above roughly 60% of VO₂max and remains elevated for hours, supporting gluconeogenesis. ADH and aldosterone rise, defending plasma volume against sweat loss. Testosterone and estrogen rise acutely during resistance work.

The paradox worth understanding. Working muscle takes up glucose while insulin is falling. It can do this because muscle contraction itself triggers GLUT4 translocation through an insulin-independent pathway involving AMP-activated protein kinase. Contraction and insulin are two separate keys to the same door.

That fact is the whole reason exercise treats type 2 diabetes. A muscle whose insulin receptors have down-regulated still has a functioning contraction-activated pathway. Exercise lowers blood glucose in a person whose insulin does not work — which is why a patient with a fasting glucose of 212 mg/dL can bring it down with a walk.

With training, over weeks. The reliable adaptations are: increased GLUT4 protein content in muscle (often 30–100%), increased mitochondrial density and oxidative enzyme capacity, increased capillary density improving insulin and glucose delivery, reduced intramyocellular lipid, and reduced visceral adipose mass. Resting insulin falls, resting catecholamines fall, and the catecholamine response to a fixed submaximal workload falls.

The single most important claim in this sidebar: the improvement in insulin sensitivity from exercise is largely independent of weight loss. A single session improves insulin action for 16 to 48 hours; a training program improves it measurably in people whose body mass has not changed at all. Because the effect decays within about three days, the clinical prescription follows directly from the physiology: frequency matters more than duration. Thirty minutes most days beats three hours on Sunday, and that recommendation is not a guess — it is the decay curve of a GLUT4 pool.

This is the physiological argument behind Amara's cardiac rehabilitation program (Chapter 10), and it is the one intervention on her problem list that treats her heart, her glucose, her blood pressure, and her triglycerides simultaneously.

Case File 16 · Question 1 resolved here

Amara's insulin is 28 µU/mL and her glucose is 212 mg/dL because the insulin signal is being sent and not received. Her beta cells work; her receptors do not. The high insulin is not the disease — it is the measurement of how hard the control system is working against a failed effector. If you treated the high insulin, you would kill her. If you treat the failed effector, both numbers fall together. The full argument is assembled in the Case File Resolution.

Check Your Understanding 16.8

  1. Why is C-peptide measured to distinguish type 1 from type 2 diabetes, and why does it also identify a patient secretly injecting insulin?
  2. A person with type 1 diabetes who misses insulin doses develops ketoacidosis; a person with type 2 diabetes and the same blood glucose usually does not. Explain using adipose tissue.
Show answers
  1. Insulin is made as proinsulin and cleaved into insulin plus C-peptide, released in equimolar amounts. C-peptide is therefore a marker of endogenous beta-cell output. It is absent in type 1 (no beta cells) and normal or high in type 2 (beta cells working hard). Its diagnostic elegance is that injected insulin contains no C-peptide, so a patient with hypoglycemia, high insulin, and suppressed C-peptide is receiving insulin from outside — either surreptitiously or by error. High insulin with high C-peptide points instead to an insulin-secreting tumor or a sulfonylurea. One measurement separates three causes.
  2. Because ketogenesis requires unrestrained lipolysis. Insulin's most sensitive action is inhibition of hormone-sensitive lipase in adipose tissue — it takes very little insulin to hold lipolysis in check. In type 1 there is no insulin, so fatty acids flood the liver and are converted to ketoacids. In type 2 there is plenty of insulin, and although muscle and liver are resistant, adipose tissue's antilipolytic response is comparatively preserved, so lipolysis stays suppressed and ketones do not accumulate. The type 2 patient instead decompensates by a different route — extreme hyperglycemia with osmotic diuresis and dehydration, the hyperosmolar hyperglycemic state.

16.9 The Rest of the Endocrine System

Several organs whose main job is something else also secrete hormones — and in aggregate they matter as much as the classical glands.

                    THE ENDOCRINE ORGANS OF THE BODY

   ╭─────────────────────────────────────────────────────────────────╮
   │  PINEAL  (epithalamus)                                          │
   │    MELATONIN — dark-signal; entrains circadian rhythm           │
   │  HYPOTHALAMUS                                                    │
   │    releasing/inhibiting hormones; makes ADH + oxytocin           │
   │  PITUITARY  (sella turcica)                                      │
   │    ANTERIOR  GH TSH ACTH FSH LH PRL                              │
   │    POSTERIOR ADH  oxytocin  (released, not made, here)           │
   ╰─────────────────────────────────────────────────────────────────╯
                                  │  neck
   ╭─────────────────────────────────────────────────────────────────╮
   │  THYROID (anterior trachea)  T4, T3 — metabolic rate             │
   │                              calcitonin — lowers Ca²⁺            │
   │  PARATHYROIDS (4, posterior thyroid)  PTH — raises Ca²⁺          │
   ╰─────────────────────────────────────────────────────────────────╯
                                  │  thorax
   ╭─────────────────────────────────────────────────────────────────╮
   │  THYMUS (mediastinum)  thymosin/thymopoietin — T-cell maturation │
   │  HEART (atria)         ANP, BNP — natriuresis; OPPOSE the RAAS   │
   ╰─────────────────────────────────────────────────────────────────╯
                                  │  abdomen
   ╭─────────────────────────────────────────────────────────────────╮
   │  ADRENAL (on each kidney)                                        │
   │     CORTEX  aldosterone · cortisol · androgens                   │
   │     MEDULLA epinephrine · norepinephrine                         │
   │  PANCREAS (islets)  insulin · glucagon · somatostatin            │
   │  KIDNEY   ERYTHROPOIETIN (RBC production, Ch.17) · RENIN ·       │
   │           CALCITRIOL activation                                  │
   │  STOMACH / GUT  gastrin · ghrelin (hunger) · secretin · CCK ·    │
   │                 GLP-1 (incretin: amplifies insulin release)      │
   │  LIVER    angiotensinogen · IGF-1 · hepcidin · thrombopoietin    │
   │  ADIPOSE  LEPTIN (satiety, energy stores) · ADIPONECTIN          │
   │           (insulin-sensitising) · resistin · TNF-α · IL-6        │
   │  BONE     osteocalcin · FGF23 (phosphate excretion)              │
   ╰─────────────────────────────────────────────────────────────────╯
                                  │  pelvis
   ╭─────────────────────────────────────────────────────────────────╮
   │  OVARIES  estrogens · progesterone · inhibin · relaxin           │
   │  TESTES   testosterone · inhibin                                 │
   │  PLACENTA (pregnancy only)  hCG · human placental lactogen ·     │
   │           estrogen · progesterone — the largest temporary        │
   │           endocrine organ a human ever builds                    │
   ╰─────────────────────────────────────────────────────────────────╯

Figure 16.7 — Whole-body map of endocrine tissue, including organs whose primary function is not endocrine.

Described: A head-to-pelvis map in five grouped regions. In the head: the pineal gland of the epithalamus secreting melatonin, the dark signal that entrains circadian rhythm; the hypothalamus, making releasing and inhibiting hormones plus ADH and oxytocin; and the pituitary in the sella turcica, whose anterior lobe makes growth hormone, TSH, ACTH, FSH, LH, and prolactin and whose posterior lobe releases, but does not make, ADH and oxytocin. In the neck: the thyroid on the anterior trachea, making T4 and T3 for metabolic rate and calcitonin to lower calcium; and four parathyroid glands on its posterior surface making parathyroid hormone to raise calcium. In the thorax: the thymus in the mediastinum, making thymosin and thymopoietin for T-cell maturation; and the heart's atria, making atrial and B-type natriuretic peptides that promote sodium excretion and oppose the renin–angiotensin–aldosterone system. In the abdomen: the adrenal glands capping each kidney, cortex making aldosterone, cortisol, and androgens and medulla making epinephrine and norepinephrine; the pancreatic islets making insulin, glucagon, and somatostatin; the kidney making erythropoietin for red cell production, renin, and activated vitamin D; the stomach and gut making gastrin, ghrelin for hunger, secretin, cholecystokinin, and the incretin GLP-1 that amplifies insulin release; the liver making angiotensinogen, IGF-1, hepcidin, and thrombopoietin; adipose tissue making leptin for satiety, the insulin-sensitising hormone adiponectin, resistin, and the inflammatory cytokines TNF-alpha and interleukin-6; and bone making osteocalcin and FGF23, which promotes phosphate excretion. In the pelvis: the ovaries making estrogens, progesterone, inhibin, and relaxin; the testes making testosterone and inhibin; and, in pregnancy only, the placenta making human chorionic gonadotropin, human placental lactogen, estrogen, and progesterone — the largest temporary endocrine organ a human ever builds.

The pineal gland, melatonin, and the clock

The pineal gland is a small (0.1–0.2 g) structure in the epithalamus, at the posterior roof of the third ventricle. It secretes melatonin, synthesized from tryptophan via serotonin, and it does so only in darkness.

The pathway is worth tracing because it explains Amara. Specialized retinal ganglion cells containing melanopsin respond to light — most strongly to short-wavelength blue light — and project through the retinohypothalamic tract to the suprachiasmatic nucleus (SCN) of the hypothalamus, the body's master clock. The SCN projects, via a circuitous route through the paraventricular nucleus and the superior cervical ganglion, to the pineal. Light inhibits that pathway. Darkness releases it, and melatonin rises, peaking between 02:00 and 04:00 and falling to near-zero by mid-morning.

Melatonin is therefore not a sleep hormone in the sense of a sedative. It is a darkness signal — a chemical announcement of biological night, which every tissue in the body reads. The SCN also drives the cortisol rhythm, the core temperature rhythm, and daily variation in blood pressure, insulin sensitivity, and gastric emptying. When the light-dark cycle and the behavior cycle disagree, they all desynchronize together. This is the answer to Amara's second question, developed in full in the Resolution below.

Endocrine functions of "non-endocrine" organs

Organ Hormone Action and where it recurs
Heart (atrial myocytes) Atrial natriuretic peptide (ANP); ventricles make BNP under stretch Released when atria are stretched by volume overload. Promotes sodium and water excretion, vasodilates, and inhibits renin, aldosterone, and ADH — the direct antagonist of the RAAS. BNP is measured clinically as a marker of ventricular stretch and heart failure (Chapters 18, 26)
Kidney Erythropoietin (EPO) Peritubular fibroblasts sense low oxygen and secrete EPO, which drives red cell production in marrow. Kidney disease therefore causes anemia (Chapter 17)
Kidney Renin; calcitriol §16.7; §16.6
Stomach / gut Gastrin Stimulates gastric acid secretion (Chapter 23)
Stomach Ghrelin The hunger hormone: rises before meals, falls after. The only known peripheral appetite stimulant
Small intestine GLP-1, GIP (incretins) Released by nutrient arrival; amplify glucose-stimulated insulin secretion. Oral glucose causes far more insulin release than the same glucose given intravenously — the incretin effect, and the basis of an entire modern drug class
Adipose tissue Leptin Secreted in proportion to fat mass; signals the hypothalamus that energy stores are adequate, reducing appetite. In obesity leptin is high and ineffective — leptin resistance, the same down-regulation logic as insulin resistance
Adipose tissue Adiponectin Improves insulin sensitivity and is anti-inflammatory. Uniquely, it falls as fat mass rises — especially visceral fat
Adipose tissue TNF-α, IL-6, resistin Pro-inflammatory; directly impair insulin receptor signaling. Visceral adipose tissue is an endocrine organ that secretes insulin resistance
Bone Osteocalcin Osteoblast product; in its undercarboxylated form it increases insulin secretion and sensitivity — bone talks back to the pancreas
Bone (osteocytes) FGF23 Promotes renal phosphate excretion and suppresses calcitriol; rises early in chronic kidney disease
Liver Angiotensinogen, IGF-1, hepcidin, thrombopoietin Substrate for the RAAS; mediator of GH; iron-absorption regulator; platelet production
Thymus Thymosin, thymopoietin T-lymphocyte maturation; the gland involutes after puberty (Chapter 20)
Gonads Estrogens, progesterone, testosterone, inhibin Chapter 27
Placenta hCG, hPL, estrogen, progesterone Chapter 28

Adipose tissue deserves the emphasis it gets in that table. Until the 1990s fat was regarded as inert storage. It is now understood as the largest endocrine organ in most adults, and its secretory profile changes with its distribution: visceral adipose tissue is far more metabolically active, more inflammatory, and drains directly into the hepatic portal vein, delivering free fatty acids and cytokines straight to the liver. That anatomical detail is why waist circumference predicts metabolic disease better than body mass index — and why Amara's 96 cm waist is a more informative number than her BMI of 29.3.

Aging · The Endocrine System from 20 to 90

Endocrine aging is not uniform. Some axes fail, some drift, and some are untouched.

Largely preserved: thyroid hormone production (TSH drifts slightly up, but free T4 stays normal in healthy elders); parathyroid function; ADH release, though the kidney's response to it declines.

Declines steadily: Growth hormone and IGF-1 fall roughly 15% per decade after 30 — the "somatopause" — contributing to reduced lean mass, increased fat mass, and thinner skin. Adrenal androgens (DHEA) fall by 70–80% from their peak in the twenties, while cortisol is maintained or rises slightly; the ratio shifts toward catabolism. Melatonin amplitude falls markedly, partly because the aging lens yellows and transmits less blue light to the retinal melanopsin cells — an optical cause of an endocrine change. Renin and aldosterone fall 30–50%, which is why older adults are more prone both to hyponatremia and to orthostatic hypotension.

Fails abruptly (female) or gradually (male): ovarian estrogen production ends over a few years at menopause, typically age 45–55, with a compensatory rise in FSH and LH that is diagnostic; testicular testosterone falls perhaps 1% per year from age 40 with a much more variable picture (Chapter 27). Amara at 45 is entering the perimenopausal transition, and the loss of estrogen's vascular and lipid protection is one reason her cardiovascular risk is about to change slope.

Glucose tolerance worsens in nearly everyone. Fasting glucose rises about 1 mg/dL per decade and the two-hour post-load glucose about 5 mg/dL per decade, driven by sarcopenia (less muscle means less GLUT4 and less disposal capacity), increased visceral fat, reduced physical activity, and reduced beta-cell reserve. Aging does not cause type 2 diabetes; it lowers the threshold at which everything else does.

Check Your Understanding 16.9

  1. Why does a patient with advanced chronic kidney disease become anemic and hypocalcemic and hypertensive — three problems that look unrelated?
  2. Oral glucose produces more insulin release than the same amount of intravenous glucose. What does this prove about how insulin secretion is controlled?
Show answers
  1. Because the kidney is an endocrine gland with at least three products. Loss of erythropoietin removes the drive to red cell production, causing anemia. Loss of 1α-hydroxylase removes calcitriol, so intestinal calcium absorption falls, causing hypocalcemia and secondary hyperparathyroidism; retained phosphate makes it worse. And falling renal perfusion drives renin, so angiotensin II and aldosterone rise, causing sodium retention and vasoconstriction and therefore hypertension. Three "unrelated" problems from one organ, and a preview of Chapter 26.
  2. It proves that beta cells are not controlled by blood glucose alone. The gut detects nutrients arriving in the lumen — before they are absorbed — and releases incretins (GLP-1 and GIP) that prime the beta cell to respond more strongly to whatever glucose then arrives. This is a feed-forward mechanism: the body anticipates the glucose load rather than only reacting to it. Feed-forward control is faster and more precise than pure feedback, and the incretin effect accounts for 50–70% of the insulin response to a normal meal.

16.10 Advanced Topic · Metabolic Syndrome and the Logic of Endocrine Diagnosis

Part 1 · Metabolic syndrome as one disorder, not five

Amara's chart lists five separate problems: hypertension, hyperglycemia, hypertriglyceridemia, low HDL, and central obesity. Treated as five problems, she gets five specialists and five drugs. Treated as one problem, she gets a mechanism.

Metabolic syndrome is diagnosed when any three of five criteria are met:

Criterion Threshold Amara
Waist circumference ≥ 88 cm (women), ≥ 102 cm (men) 96 cm — met
Fasting triglycerides ≥ 150 mg/dL 244 — met
HDL cholesterol < 50 mg/dL (women), < 40 (men) 38 — met
Blood pressure ≥ 130/85 mm Hg, or treated 168/98 — met
Fasting glucose ≥ 100 mg/dL, or treated 212 — met

She meets all five. But the criteria are a screening definition, not a mechanism. The mechanism is a single chain, and insulin resistance sits at the top of it.

  1. Visceral adipose tissue expands and becomes inflamed, secreting TNF-α, IL-6, and resistin while secreting less adiponectin. Its venous drainage goes to the hepatic portal vein, so the liver receives this mixture first and at high concentration.
  2. Those cytokines, plus intracellular lipid intermediates in muscle and liver, interfere with insulin receptor substrate signaling. Insulin binds; the message does not propagate. Add the down-regulation caused by chronic hyperinsulinemia itself, and the target is doubly deaf.
  3. Beta cells compensate by secreting more insulin. Glucose is held near-normal for years — this is the long, silent, entirely asymptomatic prediabetic phase. Amara spent it working night shifts.
  4. Hyperinsulinemia has its own consequences, and they are the rest of the syndrome: - In the liver, insulin resistance is selective. Gluconeogenesis becomes resistant (so hepatic glucose output stays high, raising fasting glucose) while lipogenesis stays sensitive (so high insulin keeps driving triglyceride synthesis and VLDL export). This paradox is why the same patient has high fasting glucose and high triglycerides. - High VLDL drives cholesteryl ester exchange that depletes HDL and generates small dense LDL particles — hence the low HDL and the particularly atherogenic lipid profile. - In the kidney, insulin promotes sodium reabsorption in the proximal tubule, and in the sympathetic nervous system it raises tone. Both raise blood pressure. - In the endothelium, insulin normally stimulates nitric oxide production; resistance removes that vasodilator signal while leaving the vasoconstrictor endothelin pathway intact. Vascular tone rises and endothelial function deteriorates (Chapter 19).
  5. Eventually beta cells fail. After years of maximal secretion, and under the toxic effects of chronic hyperglycemia and lipid exposure, beta-cell mass and function decline. Insulin falls, glucose climbs steeply, and overt type 2 diabetes appears. Amara's insulin of 28 µU/mL says she is late in the compensating phase, not yet in the failing one — which is precisely the moment when intervention still works well.

One lesion, five diagnoses, and a single treatment strategy — restore insulin sensitivity — that improves all five at once. That is what a mechanism buys you over a list.

Part 2 · Primary, secondary, tertiary: how to localize an endocrine lesion

Endocrinology is, more than any other field, a logic problem, and the logic has one rule:

Never measure a hormone alone. Measure it together with the hormone that controls it, and ask whether the pair makes sense.

In a three-tier axis, a peripheral hormone level by itself tells you that something is wrong. The pair tells you where.

Level of lesion Name Peripheral hormone Tropic hormone Interpretation
Tier 3 — the gland Primary Low High Pituitary is shouting; gland cannot answer
Tier 2 — pituitary Secondary Low Low or inappropriately normal Nobody is shouting
Tier 1 — hypothalamus Tertiary Low Low, but rises after giving the releasing hormone The pituitary works; it is not being told
Tier 3 autonomous Primary excess High Suppressed Gland is making hormone outside feedback
Tier 2 autonomous Secondary excess High High — inappropriately Pituitary tumor driving a normal gland

Two examples, worked.

A patient is tired, cold, and constipated. Free T4 is low. If TSH is 42 mU/L, the pituitary is working perfectly and the thyroid has failed: primary hypothyroidism (usually Hashimoto's). If TSH is 1.1 mU/L, that value is inappropriately normal — a healthy pituitary facing that free T4 would produce a TSH ten times higher — so the lesion is central: secondary or tertiary hypothyroidism, and the next step is an MRI of the pituitary and a check of the other five anterior hormones.

A patient has central obesity, striae, and hypertension. Cortisol is high. If ACTH is suppressed, the adrenal is autonomous: an adrenal tumor. If ACTH is high, something is driving the adrenal, and the question becomes what. A high-dose dexamethasone suppression test distinguishes: a pituitary adenoma retains some feedback sensitivity and suppresses, while an ectopic ACTH source — classically a small-cell lung carcinoma — has no feedback receptors at all and does not suppress. The test is the feedback loop used as a diagnostic instrument.

The generalizable principle: stimulation tests diagnose deficiency; suppression tests diagnose excess. If you suspect a gland is failing, stimulate it and see whether it can respond. If you suspect a gland is autonomous, suppress it and see whether it obeys. In both cases you are asking the same question — is this gland still inside its feedback loop?

Predict This

Amara's plasma renin activity is 4.8 ng/mL/h (high) and her aldosterone is 22 ng/dL (high).

Using only the rule above — measure the hormone with the hormone that controls it — decide whether her adrenal gland is the problem, and state what her renin would have to be for a primary adrenal tumor to be the answer.

(Answer: the adrenal is not the problem. Aldosterone is high because renin, its controller, is high — the gland is responding correctly to an inappropriate signal. This is secondary hyperaldosteronism. For a primary aldosterone-producing adenoma, aldosterone would be high and renin would be suppressed, because autonomous aldosterone raises volume and renal perfusion, which shuts renin off. The aldosterone-to-renin ratio formalizes exactly this reasoning.)

Chapter Summary

§16.1 The endocrine system controls by chemical broadcast through the bloodstream; the nervous system controls by wired electrical signaling. Endocrine control is slower to start, far longer-lasting, and targeted chemically rather than anatomically — only cells bearing the receptor respond. Signal strength is coded as concentration rather than firing frequency, which is why hormones can be measured and nerve traffic cannot. The two systems overlap extensively in the hypothalamus, the posterior pituitary, and the adrenal medulla.

§16.2 Hormones are amino-acid-based (water-soluble) or steroid (lipid-soluble), with thyroid hormone the lipid-soluble exception among amino-acid derivatives. Solubility determines transport (free versus carrier-bound), half-life (minutes versus days), receptor location (surface versus intracellular), mechanism (second-messenger cascade versus direct gene activation), and latency (seconds versus hours). Second-messenger cascades amplify a signal 10⁶–10⁸-fold. Target-cell specificity resides in the receptor, and receptor number is regulated: chronic high hormone causes down-regulation, the molecular basis of insulin resistance.

§16.3 Glands are stimulated humorally, neurally, or hormonally, and are almost always governed by negative feedback. Three-tier axes (hypothalamus → pituitary → gland) provide amplification, integration with the rest of the brain, multiple feedback points, and — because two levels can be measured together — diagnostic localization.

§16.4 The pituitary is two organs: a neural posterior lobe that stores and releases hypothalamically made ADH and oxytocin, and a glandular anterior lobe controlled through the hypophyseal portal system, a private two-capillary-bed circuit that delivers hypothalamic hormones at thousands of times systemic concentration. Six anterior hormones: GH, TSH, ACTH, FSH, LH, prolactin — the last under dominant inhibitory dopaminergic control.

§16.5 Thyroid follicles store hormone extracellularly as iodinated thyroglobulin in colloid. Synthesis requires iodide trapping, thyroglobulin secretion, peroxidase-mediated iodination and coupling, and TSH-triggered endocytosis. T4 is the prohormone and reservoir; peripheral deiodination makes the active T3. Thyroid hormone sets basal metabolic rate and is permissive for catecholamine action. Graves and Hashimoto disease are mirror images distinguished by TSH.

§16.6 PTH defends ionized calcium through bone (osteoclast activation via osteoblast RANK ligand), kidney (calcium reabsorption plus phosphate excretion), and intestine (indirectly, via calcitriol). Bone is a thousandfold reservoir, and the price of defending plasma calcium over decades is paid in skeletal mass.

§16.7 The adrenal cortex zones map to products — glomerulosa/aldosterone, fasciculata/cortisol, reticularis/androgens — while the medulla is a modified sympathetic ganglion secreting catecholamines. The RAAS converts a fall in renal perfusion into vasoconstriction, sodium retention, thirst, and ADH release, defending arterial pressure on four timescales, and remodels heart and vessels when sustained. Cortisol mobilizes fuel, opposes insulin, is permissive for vascular catecholamine responses, and suppresses inflammation; the general adaptation syndrome ends in an exhaustion phase whose costs are Amara's problem list.

§16.8 Beta cells sense glucose directly and secrete insulin, which drives GLUT4 into muscle and fat membranes and switches the whole body to storage; alpha cells secrete glucagon, which switches the liver to output. Type 1 diabetes is failure of the signal; type 2 is failure of the target. The distinction determines treatment.

§16.9 Melatonin from the pineal is a darkness signal read by the SCN-driven circadian system that also times cortisol, temperature, and insulin sensitivity. Heart, kidney, gut, liver, bone, adipose tissue, and placenta are all endocrine organs; visceral fat in particular secretes inflammatory mediators directly into portal blood.

§16.10 Metabolic syndrome is one mechanism — insulin resistance with compensatory hyperinsulinemia — presenting as five diagnoses. Endocrine lesions are localized by measuring a hormone together with its tropic hormone: stimulation tests diagnose deficiency, suppression tests diagnose excess.

The Three Threads in Chapter 16

Structure → Function. The hypophyseal portal system is a vascular structure that exists for one reason: to keep a message concentrated and private. The thyroid follicle is a storage tank built inside a gland. The adrenal cortex's three zones are three enzyme complements arranged in concentric shells, and you can predict each zone's hormone from its position. And at the molecular scale, a hormone's solubility — a property of its chemical structure — dictates its transport, half-life, receptor location, mechanism, and latency.

Homeostasis. Every endocrine system in this chapter is a negative feedback loop, and the chapter's central pathology is what happens when one of them is defeated. Amara's beta cells are working perfectly and failing completely, because a loop that measures the variable rather than the response cannot detect a broken effector — it can only push harder. And the RAAS, reading renal perfusion as a proxy for volume, becomes destructive the moment that proxy stops being true.

Integration. The RAAS alone links kidney, liver, lung, adrenal cortex, arteriole, brain, and heart in one circuit. Add the fact that fat, bone, gut, and heart muscle are all endocrine tissue, and the last defensible boundary between "the endocrine system" and "the body" disappears. Amara's night shift reaches her coronary arteries through the pineal gland, the suprachiasmatic nucleus, the adrenal cortex, adipose tissue, and the endothelium — five systems in one causal chain, none of which is the cardiovascular system.

Case File 16 · Resolution

Question 1 — How can Amara's insulin be high (28 µU/mL) and her glucose also be high (212 mg/dL)? Which number is the disease?

Neither number is the disease. The disease is the broken connection between them.

Work the feedback loop box by box (§1.5, §16.8). The variable is blood glucose. The sensor and control center is the pancreatic beta cell, which senses glucose directly through glucokinase and ATP-sensitive potassium channels. The efferent signal is insulin. The effectors are skeletal muscle, adipose tissue, and liver, which must respond by inserting GLUT4 and switching to storage.

Amara's sensor works — her beta cells clearly detect the glucose, because they are secreting more than twice the normal amount of insulin. Her control center works. Her signal is being sent, in excess. What is not happening is the response: her muscle and fat cells have down-regulated and functionally uncoupled their insulin receptors (§16.2). Insulin binds, and the message does not propagate to GLUT4.

This is insulin resistance, and the causal chain that produced it is in §16.10: expanded, inflamed visceral adipose tissue — her waist is 96 cm — secreting TNF-α, IL-6, and resistin into portal blood while secreting less adiponectin; lipid intermediates accumulating inside muscle and liver cells and interfering with insulin receptor substrate signaling; and chronic hyperinsulinemia itself driving further receptor down-regulation. Add the counter-regulatory effect of a flattened, elevated night-time cortisol (Question 2), and the target is deaf from four directions at once.

So her high insulin is not a paradox and it is not an error. It is the measured output of a control system applying maximum effort to an effector that cannot respond. It is the physiological equivalent of a thermostat with a dead furnace: the more the room cools, the harder the thermostat calls for heat, and the reading on the control panel goes up while the room gets colder.

Three consequences follow immediately, and all three are clinically important.

She is not "almost out of insulin." Her beta cells still have reserve. Her HbA1c of 7.4% reflects an average glucose around 166 mg/dL, which is elevated but far from the values seen when beta cells fail. She is late in the compensating phase of §16.10, step 4 — which is exactly the phase in which intervention still restores function.

Giving her more insulin would be the wrong first move. You cannot fix a broken effector by increasing the signal; you would simply drive further down-regulation and promote weight gain, which worsens the underlying problem. The first-line treatments — exercise, weight reduction, and metformin — all work by restoring the response rather than adding signal.

Her hyperinsulinemia is itself pathogenic. High insulin promotes renal sodium reabsorption (raising blood pressure), hepatic lipogenesis and VLDL export (raising her triglycerides to 244 mg/dL and depleting her HDL to 38), and sympathetic activation. Four of her five metabolic syndrome criteria are downstream of the hormone that was supposed to be helping.

Question 2 — What does twenty years of night shift do to cortisol, and why would that matter to a coronary artery?

Amara's cortisol is not high at any single measurement. What is abnormal is its shape: a flattened curve with a nighttime value (0.24 µg/dL at 23:00) nearly equal to her morning value, where it should be almost undetectable. That flattening is the endocrine fingerprint of chronic circadian misalignment, and the mechanism runs through §16.9.

The suprachiasmatic nucleus is entrained by light striking melanopsin-containing retinal ganglion cells. It drives the melatonin rhythm through the pineal, and — through CRH neurons in the paraventricular nucleus — the cortisol rhythm as well. A night-shift worker inverts the behavioral cycle but cannot invert the light cycle: she is exposed to bright light at night, to daylight on the commute home, and sleeps in a room that is never fully dark. The SCN receives contradictory information and the downstream rhythms desynchronize and flatten rather than cleanly shifting. Twenty years of this produces exactly what her chart shows.

Four consequences, and each one reaches the coronary artery by a different road.

Cortisol is a counter-regulatory hormone. Nocturnal cortisol that should be near zero instead maintains gluconeogenesis, promotes protein catabolism, and directly impairs GLUT4 translocation in muscle and fat. It is, in effect, a low-grade continuous infusion of a diabetogenic hormone across the hours when insulin sensitivity should be recovering. Her insulin resistance (Question 1) is partly cortisol's doing.

Cortisol redistributes fat centrally. Chronically elevated glucocorticoid exposure promotes visceral adipose deposition specifically, and visceral fat is the inflammatory, portal-drained, adiponectin-poor depot that generates insulin resistance. Her waist circumference of 96 cm is a partly endocrine finding.

Cortisol and misalignment raise blood pressure. Cortisol is permissive for vascular catecholamine responsiveness and, at higher concentrations, activates mineralocorticoid receptors, promoting sodium retention. Circadian misalignment also blunts the normal nocturnal blood pressure dip — a phenomenon called non-dipping, which independently predicts cardiovascular events. Blood pressure that never rests is a vessel wall that never rests.

Cortisol modulates inflammation, and chronic exposure dysregulates it. Acutely cortisol is anti-inflammatory, but chronic exposure produces glucocorticoid resistance in immune cells — receptor down-regulation again, the same mechanism as her insulin resistance in a different cell type. The result is a persistent low-grade inflammatory state, and atherosclerosis is an inflammatory disease of the arterial wall (Chapters 19 and 20). Inflamed endothelium recruits monocytes, takes up oxidized LDL, and builds plaque; and it is plaque rupture, not gradual narrowing, that produces the event that brought her to the emergency department.

So the causal chain from her work schedule to her coronary artery is fully specifiable: light at the wrong time → SCN desynchronization → flattened cortisol and suppressed nocturnal melatonin → insulin resistance + visceral adiposity + non-dipping hypertension + chronic inflammation → endothelial dysfunction and accelerated atherogenesis → plaque → chest pain at 07:40 on a Tuesday. Not one step of that chain is inside the cardiovascular system until the very end. This is why occupational history is a cardiac risk factor and not small talk.

Question 3 — What is aldosterone doing in a story about the heart?

Three things, and each one is a different kind of answer.

First, it is telling you what her kidneys think is happening. Aldosterone is high because renin is high (§16.7, §16.10), and renin is high because her kidneys are sensing inadequate perfusion — through reduced afferent arteriolar stretch, reduced sodium delivery to the macula densa, and heavy beta-1 sympathetic drive on the granular cells. Her sympathetic tone has been elevated since triage. Her arterioles are stiff and narrowed. Her cardiac output is compromised by an ischemic ventricle. The kidney cannot distinguish any of that from hemorrhage, so it activates the loop that would be correct if it were hemorrhage. Her high renin and high aldosterone are a readout of renal perfusion, which is a readout of the heart.

Second, it is actively making her heart's job harder. Aldosterone retains sodium and therefore water, raising blood volume and venous return — which raises preload on a ventricle that is already struggling. Angiotensin II constricts arterioles, raising afterload — the pressure the same ventricle must overcome to eject. A failing heart responds to both by working harder and consuming more oxygen, in a coronary circulation that cannot deliver more oxygen. This is the cardiorenal loop described in the Thread 2 sidebar in §16.7, and it is the reason her blood pressure of 168/98 is not merely a number but a load.

Third, and least obvious, it is remodeling her heart muscle. Angiotensin II and aldosterone are growth factors as well as pressure hormones. Sustained, they drive cardiac myocyte hypertrophy and stimulate fibroblasts to lay down collagen between myocytes. A ventricle with excess interstitial collagen is stiff — it contracts adequately but cannot relax and fill properly. That is the pathological basis of heart failure with preserved ejection fraction, which is where Amara's arc is heading (Chapter 18). The remodeling is happening now, silently, in the tissue, driven by a hormone measured in a tube of blood on hospital day two.

This is also why the drugs she will be started on make sense. An ACE inhibitor or ARB interrupts the loop at angiotensin II; a mineralocorticoid receptor antagonist such as spironolactone blocks aldosterone at the collecting duct and at the cardiac fibroblast. Both classes improve survival in heart failure by more than their blood-pressure effect alone predicts — because they are not only lowering a number, they are switching off a growth signal.

Somebody ordered a renin and an aldosterone on a woman with chest pain because those two values describe the load her heart is working against, the reason that load exists, and the mechanism by which it will remodel her ventricle over the next two years. That is not an endocrine test. It is a cardiac one.

Systems Integration Case File · Entry 16

Entry 16 — The endocrine system enters the model

New findings for your file, hospital day 2:

  • Fasting glucose 212 mg/dL; HbA1c 7.4%; fasting insulin 28 µU/mL (high)
  • Waist 96 cm; triglycerides 244 mg/dL; HDL 38 mg/dL
  • Plasma renin activity 4.8 ng/mL/h (high); aldosterone 22 ng/dL (high)
  • Salivary cortisol flattened and phase-shifted; 23:00 value 0.24 µg/dL (should be < 0.09)
  • Meets all five criteria for metabolic syndrome

Your entry:

1 · ADD. In two to three sentences, state what the endocrine system contributes to Amara's picture. Name the specific box of the glucose feedback loop that has failed, and use her actual insulin and glucose values to justify it.

2 · CONNECT. Link the endocrine findings to at least two systems already in your file, stating the direction of causation each time. Strong entries will connect to the nervous system (Chapters 11–13) and the cardiovascular findings from Chapter 1, and will name at least one complete feedback loop.

3 · PREDICT. Name one finding you expect in Chapter 17, 16, 17, or 22 that follows from what you have just added, and say why.

Model responses — read only after writing your own

1 · ADD. The endocrine system supplies the mechanism that unifies Amara's five separate diagnoses. Her fasting insulin of 28 µU/mL alongside a glucose of 212 mg/dL localizes the failure to the effector/target box: the signal is being sent at more than twice the normal rate and the muscle, liver, and adipose receptors are not responding, which is insulin resistance rather than insulin deficiency. Her simultaneously elevated renin and aldosterone, and her flattened cortisol rhythm, are two further endocrine systems reading and worsening the same picture.

2 · CONNECT. Nervous → endocrine: twenty years of night shift has desynchronized the suprachiasmatic nucleus, which flattens the CRH–ACTH–cortisol rhythm; the resulting nocturnal cortisol directly impairs GLUT4 translocation and promotes visceral fat deposition, so a central nervous system timing problem causes a peripheral metabolic one. Endocrine → cardiovascular: hyperinsulinemia increases proximal tubular sodium reabsorption and sympathetic tone, and the elevated renin–angiotensin–aldosterone axis adds volume expansion (preload) and arteriolar constriction (afterload), so endocrine signals cause the blood pressure of 168/98 recorded in Chapter 1. Cardiovascular → endocrine, closing the loop: her ischemic, poorly perfusing ventricle reduces renal perfusion pressure, which causes granular cells to secrete renin — the cardiorenal loop, in which a compensatory mechanism worsens the problem it is compensating for. Integumentary and autonomic: the same sympathetic activation that made her skin cool and pale in triage is also driving renin release through beta-1 receptors, one efferent signal producing two findings in two systems.

3 · PREDICT. Several defensible answers. (a) Chapter 17: expect anemia, because the same processes damaging her kidneys reduce erythropoietin, and because chronic low-grade inflammation sequesters iron. (b) Chapter 18: expect a stiff, non-dilated left ventricle with preserved ejection fraction, because angiotensin II and aldosterone are growth factors driving myocyte hypertrophy and interstitial collagen deposition. (c) Chapter 19: expect endothelial dysfunction and elevated systemic vascular resistance, because insulin resistance removes insulin's nitric-oxide-mediated vasodilator effect while leaving vasoconstrictor pathways intact. (d) Chapter 26: expect a rising creatinine and falling GFR, because sustained angiotensin II causes glomerular hypertension and sclerosis, and because hyperglycemia damages the glomerular basement membrane.

Review

Level 1 · Recall

14.1 Which property best predicts whether a hormone's receptor is on the cell surface or inside the cell?

a) molecular weight    b) lipid solubility    c) gland of origin    d) plasma half-life

Answer

b — lipid solubility. A lipid-soluble hormone crosses the plasma membrane freely, so its receptor can be intracellular; a water-soluble hormone cannot cross, so its receptor must be on the surface. Molecular weight correlates loosely but fails for thyroid hormone, which is tiny and yet uses a nuclear receptor. Half-life is a consequence of solubility, not a predictor of receptor location, and gland of origin predicts nothing — the adrenal makes both classes.

14.2 The hypophyseal portal system carries blood from:

a) the anterior pituitary to the hypothalamus    b) the hypothalamus to the posterior pituitary    c) a capillary bed in the median eminence to a capillary bed in the anterior pituitary    d) the pituitary to the systemic circulation

Answer

c. A portal system is defined by two capillary beds in series connected by a vein. Blood picks up releasing hormones in the median eminence and delivers them, undiluted, to the anterior lobe. Option b describes the hypothalamic–hypophyseal tract, which is axonal, not vascular, and serves the posterior lobe.

14.3 A patient has a low free T4 and a TSH of 38 mU/L (normal 0.4–4.0). The lesion is:

a) primary — in the thyroid    b) secondary — in the pituitary    c) tertiary — in the hypothalamus    d) not determinable without an MRI

Answer

a — primary. The pituitary is functioning correctly: it detects the low hormone and responds with a large rise in TSH. The failure is in the gland that cannot answer. A secondary or tertiary lesion would show a low or inappropriately normal TSH alongside the low T4.

14.4 Which zone of the adrenal cortex secretes aldosterone, and what is its dominant regulator?

a) fasciculata; ACTH    b) glomerulosa; angiotensin II    c) reticularis; LH    d) medulla; sympathetic nerves

Answer

b — zona glomerulosa, regulated by angiotensin II and by plasma potassium, with only weak ACTH influence. This is why a patient with panhypopituitarism loses cortisol but retains aldosterone, and therefore does not develop the severe hyperkalemia of primary adrenal failure.

14.5 Renin is best described as:

a) a steroid hormone from the adrenal cortex    b) an enzyme secreted by the kidney that cleaves angiotensinogen    c) a peptide hormone that acts on arterioles    d) an enzyme on lung endothelium

Answer

b. Renin has no receptor and no target cell; it performs one proteolytic cleavage. Option d describes angiotensin-converting enzyme. Option c describes angiotensin II. Because angiotensinogen is always available in excess, renin secretion is the rate-limiting step of the whole cascade — which is why plasma renin activity is the measurement that matters.

14.6 Which pattern is characteristic of type 2 diabetes early in its course?

a) low insulin, low C-peptide    b) high insulin, high C-peptide    c) high insulin, absent C-peptide    d) low insulin, high C-peptide

Answer

b. Beta cells are intact and working overtime against resistant targets, so both insulin and its co-secreted partner C-peptide are elevated. Option a is type 1. Option c indicates injected insulin, since exogenous insulin contains no C-peptide. Option d is not physiological, since the two are secreted in equimolar amounts.

14.7 Parathyroid hormone increases blood calcium by all of the following EXCEPT:

a) stimulating osteoclast activity indirectly through osteoblasts    b) increasing calcium reabsorption in the distal tubule    c) increasing renal phosphate reabsorption    d) stimulating renal 1α-hydroxylase to produce calcitriol

Answer

c. PTH decreases phosphate reabsorption, causing phosphaturia. This is essential rather than incidental: bone resorption liberates calcium and phosphate together, and if both rose they would precipitate as calcium phosphate in soft tissue. Excreting phosphate keeps the liberated calcium in solution.

14.8 Melatonin secretion by the pineal gland is:

a) stimulated by light    b) inhibited by light via the retinohypothalamic tract and suprachiasmatic nucleus    c) independent of the light–dark cycle    d) controlled by ACTH

Answer

b. Melanopsin-containing retinal ganglion cells signal the suprachiasmatic nucleus, which inhibits the sympathetic pathway to the pineal. Melatonin is therefore a darkness signal, and light at night suppresses it — the mechanism behind shift-work desynchronization and behind the recommendation to avoid bright screens before sleep.

Level 2 · Comprehension

14.9 Explain, using the concept of receptor down-regulation, why a hormone level that is "high" is not necessarily evidence that the hormone is doing too much.

Model answer

Hormone concentration is the output of a control system, not a measure of its effect. Negative feedback loops regulate a variable, not a response: the gland secretes until the variable corrects. If the target has down-regulated or uncoupled its receptors, the variable does not correct, so the gland secretes more — and the measured hormone rises precisely because it is failing to act. Insulin resistance is the clearest case: insulin of 28 µU/mL with a glucose of 212 mg/dL is a maximal signal producing a minimal effect. Leptin resistance in obesity and glucocorticoid resistance in chronic stress follow the same pattern. The practical rule is to interpret every hormone level alongside the variable it controls; a hormone that is high while its variable is uncorrected indicates resistance, not excess.

14.10 Antithyroid drugs take four to eight weeks to control hyperthyroidism, whereas propranolol relieves symptoms in hours. Explain both timescales.

Model answer

Antithyroid drugs such as methimazole inhibit thyroid peroxidase, blocking iodination and coupling — that is, they block synthesis. But the thyroid is unique in storing two to three months' worth of finished hormone extracellularly as iodinated thyroglobulin in colloid, and release from that store continues. The drug stops the tap; it cannot empty the tank. Additionally, T4's plasma half-life is about seven days, so even after release stops the circulating pool declines slowly. Propranolol does nothing to the thyroid at all. It blocks the beta-adrenergic receptors that thyroid hormone has up-regulated, and since receptor blockade is immediate, the adrenergic symptoms — tachycardia, tremor, anxiety, sweating — resolve within hours. Two drugs, two mechanisms, two timescales, and the combination is standard practice precisely because they act at different points.

14.11 Why must a patient on long-term prednisone taper the dose rather than stop it, and what would happen if she did not?

Model answer

Exogenous glucocorticoid is read by the feedback loop as cortisol, so CRH and ACTH are suppressed for the duration of therapy. Tropic hormones are also trophic — they maintain the mass of the gland they control — so a zona fasciculata deprived of ACTH for months atrophies. Stopping abruptly removes the exogenous steroid within a day, while the patient's own axis cannot supply cortisol: ACTH is still suppressed and the gland is too small to respond even if it were stimulated. The result is acute adrenal crisis: hypotension unresponsive to fluids (because cortisol is permissive for vascular catecholamine responsiveness), hypoglycemia, hyponatremia, hyperkalemia, vomiting, and potentially death. Tapering allows the hypothalamus and pituitary to recover first, and the returning ACTH then regrows the cortex. Recovery of a suppressed axis can take six to twelve months.

14.12 Compare the two mechanisms of hormone action on the criterion of speed, and explain why the difference is not arbitrary.

Model answer

Second-messenger cascades act in seconds because every component already exists in the cell: receptor, G protein, adenylate cyclase, protein kinase A, and the target enzymes are all sitting there, and the hormone only has to switch them on by phosphorylation. Direct gene activation takes 30 minutes to hours because it must transcribe messenger RNA and translate a new protein before anything can change. The difference is not arbitrary — it matches each hormone's job. Epinephrine must mobilize fuel and raise cardiac output now, so it uses the fast mechanism. Aldosterone adjusts sodium handling over hours to days and cortisol restructures metabolism over hours, so the slower mechanism costs them nothing and gives them a longer, steadier, more durable effect. Notice the trade-off runs both ways: a fast signal is also fast to stop, and a transcriptional signal persists as long as the protein it made.

Level 3 · Clinical Application

14.13 A 34-year-old presents with headaches, sweating, palpitations, and a blood pressure of 210/120 mm Hg during an episode that lasts twenty minutes; between episodes her pressure is 138/84. She reports a sense of terror during attacks. What is the diagnosis, what test would you order and why, and what pharmacological sequence is mandatory before surgery?

Model answer

Pheochromocytoma — a catecholamine-secreting chromaffin cell tumor. The episodic pattern is the key: an endocrine signal is concentration-coded, so a tumor that releases catecholamines in bursts produces symptoms in bursts, unlike essential hypertension, which is continuous and asymptomatic. The triad of headache, sweating, and palpitations with paroxysmal hypertension is classic.

The test is plasma free or 24-hour urinary metanephrines, not catecholamines themselves. Catecholamines are released intermittently and have half-lives under two minutes, so a sample drawn between attacks can be normal. Metanephrines are produced continuously within the tumor by catechol-O-methyltransferase and leak steadily into plasma, so they do not miss the gaps. When a hormone is intermittent, measure its metabolite.

Before surgery the patient must receive an alpha-adrenergic blocker first (such as phenoxybenzamine), for 10–14 days, and only then a beta-blocker if needed for tachycardia. Giving a beta-blocker first removes beta-2-mediated vasodilation while leaving alpha-1 vasoconstriction unopposed, which can precipitate a hypertensive crisis. Two receptor subtypes with opposite vascular effects are being driven by the same molecule, so the order of blockade determines whether the net effect is safe.

14.14 A 58-year-old man has been treated with lithium for fifteen years. He now drinks 6–8 L of water daily and passes a similar volume of dilute urine. His plasma sodium is 149 mEq/L and urine osmolality is 120 mOsm/kg. He is given desmopressin; his urine osmolality does not change. Explain the physiology and name the disorder.

Model answer

He has nephrogenic diabetes insipidus, a well-recognized complication of long-term lithium, which interferes with the collecting duct principal cell's response to ADH — chiefly by disrupting the cyclic AMP signaling that drives aquaporin-2 insertion into the apical membrane.

The physiology: without functioning aquaporins, the collecting duct is impermeable to water, so the dilute filtrate leaving the distal tubule is excreted essentially unconcentrated (urine osmolality 120 mOsm/kg against a plasma of roughly 300). Free water loss raises plasma sodium and osmolality, which stimulates hypothalamic osmoreceptors, producing intense thirst — the polydipsia is compensation, not cause.

The desmopressin test is the diagnostic pivot and it is the §16.2 logic exactly. Desmopressin is an ADH analogue: giving it supplies the signal. If the urine had concentrated, the signal had been missing and the diagnosis would be central DI. Because the urine did not change, the signal was never the problem — the target cannot respond. Signal failure versus target failure, distinguished by supplying the signal and watching. It is the same experiment that distinguishes type 1 from type 2 diabetes, and the same principle that explains Amara's insulin of 28 µU/mL.

14.15 A 29-year-old woman has gained 14 kg over eighteen months, mostly around the abdomen, with thin arms, wide purple abdominal striae, easy bruising, new hypertension, a fasting glucose of 148 mg/dL, and amenorrhea. Her 24-hour urinary free cortisol is markedly elevated. Her plasma ACTH is 68 pg/mL (normal 10–60). Where is the lesion, how would you prove it, and explain three of her physical findings mechanistically.

Model answer

She has Cushing syndrome, and the non-suppressed, indeed elevated ACTH localizes the lesion above the adrenal gland: this is ACTH-dependent disease, so an autonomous adrenal tumor is excluded (that would suppress ACTH to undetectable). The two remaining possibilities are a pituitary corticotroph adenoma (Cushing disease) or an ectopic ACTH-secreting tumor.

To distinguish them, exploit residual feedback sensitivity. A pituitary adenoma is still a corticotroph and retains some glucocorticoid receptor response, so a high-dose dexamethasone suppression test will suppress its ACTH; an ectopic source such as a small-cell lung carcinoma has no such feedback machinery and will not suppress. Inferior petrosal sinus sampling and pituitary MRI confirm. Note what is happening conceptually: the feedback loop itself is being used as the diagnostic instrument.

Three findings, mechanistically. Thin limbs with central obesity — cortisol catabolizes peripheral skeletal muscle protein to supply amino acids for gluconeogenesis while promoting lipid deposition specifically in visceral, facial, and dorsocervical depots, a regional difference in receptor biology. Purple striae and easy bruising — cortisol inhibits fibroblast collagen synthesis, so dermal collagen thins; the skin tears under the stretch of central weight gain, and the striae are purple rather than white because the thinned dermis lets subdermal vessels show through. The same collagen loss makes capillaries unsupported and easily ruptured. Hyperglycemia and amenorrhea — cortisol induces hepatic gluconeogenic enzymes and impairs GLUT4 translocation, raising glucose; and high cortisol suppresses hypothalamic GnRH pulsatility, and gonadotrophs require pulsatile GnRH to function (§16.4), so LH and FSH fall and cycles stop.

Level 4 · Integration and Synthesis

14.16 Amara is started on lisinopril (an ACE inhibitor) and spironolactone. Trace, step by step, the effect of each drug on her renin, angiotensin II, aldosterone, blood volume, blood pressure, serum potassium, and cardiac remodeling — and explain why the combination requires careful monitoring.

Model answer

Lisinopril blocks angiotensin-converting enzyme on pulmonary capillary endothelium, so angiotensin I is no longer converted. Angiotensin II falls. Consequences: arteriolar vasoconstriction is reduced, so total peripheral resistance and afterload fall; proximal tubular sodium reabsorption falls; thirst and ADH release fall; and the adrenal zona glomerulosa loses its dominant stimulus, so aldosterone falls. Less aldosterone means fewer collecting-duct ENaC channels and Na⁺/K⁺-ATPase pumps, so sodium and water are excreted — blood volume falls, reducing preload — and potassium is retained, so serum potassium rises. Renin rises, because the loss of angiotensin II removes short-loop feedback on granular cells and because perfusion pressure falls. Crucially, the fall in angiotensin II also removes a growth signal from cardiac myocytes and fibroblasts, slowing hypertrophy and interstitial collagen deposition.

Spironolactone competitively blocks the mineralocorticoid receptor in collecting duct principal cells, producing the same downstream renal effects — sodium and water loss, potassium retention — without changing aldosterone levels, which in fact rise as the loop tries to overcome the blockade. It also blocks mineralocorticoid receptors on cardiac fibroblasts, independently reducing fibrosis.

Why monitoring is required: both drugs raise potassium, by two different mechanisms at the same final common step, and their effects are additive. In a patient whose renal function is already drifting (Chapter 26) the kidney's capacity to excrete potassium is reduced as well — three insults to potassium handling at once. Potassium's entire normal range spans 1.5 mEq/L (§1.5) and hyperkalemia is arrhythmogenic. Potassium and creatinine are therefore checked within one to two weeks of starting or increasing either drug. This is a case where the correct treatment for one homeostatic problem creates a second one, and both must be watched.

14.17 Construct the complete causal chain from Amara's work schedule to her coronary plaque, naming every hormone, gland, and target tissue involved, and identify the two points at which an intervention could break the chain.

Model answer

The chain. Night-shift work exposes the retina to bright light during biological night and to daylight during biological day. Melanopsin-containing retinal ganglion cells signal the suprachiasmatic nucleus through the retinohypothalamic tract; receiving contradictory input, the SCN's output rhythms desynchronize and flatten. Two consequences follow directly. Melatonin amplitude from the pineal gland falls, weakening the darkness signal every tissue reads. And the SCN's drive to paraventricular CRH neurons loses its normal amplitude, so the CRH → ACTH → cortisol axis produces a flattened curve with an inappropriately elevated nocturnal cortisol.

Nocturnal cortisol acting on skeletal muscle and adipose tissue impairs GLUT4 translocation and promotes visceral fat deposition. Expanded visceral adipose tissue secretes TNF-α, IL-6, and resistin — and less adiponectin — directly into the hepatic portal vein, so the liver is exposed first and most. These cytokines and accumulated intracellular lipid interfere with insulin receptor substrate signaling in muscle and liver, producing insulin resistance. Beta cells compensate with hyperinsulinemia (28 µU/mL), which raises proximal tubular sodium reabsorption and sympathetic tone, drives hepatic lipogenesis and VLDL export (triglycerides 244, HDL 38), and — combined with elevated renin, angiotensin II, and aldosterone — produces hypertension of 168/98. Loss of insulin's nitric-oxide-mediated vasodilation, plus circulating inflammatory cytokines, plus small dense LDL particles, plus non-dipping nocturnal blood pressure, produce endothelial dysfunction in the coronary arteries. Dysfunctional endothelium permits LDL entry and oxidation, recruits monocytes, and builds an inflammatory atherosclerotic plaque whose fibrous cap is thinned by ongoing inflammation. Rupture of that cap produces the event of Chapter 1.

Two intervention points. Upstream: restore circadian alignment — bright light at the start of the shift, strict darkness for daytime sleep, a stable rather than rotating schedule. This attacks the chain at its origin and would improve cortisol rhythm, insulin sensitivity, and nocturnal blood pressure together. Midstream: exercise, which restores GLUT4 translocation by the contraction-activated, insulin-independent pathway and thereby breaks the chain at insulin resistance — the step from which four of her five metabolic syndrome criteria descend. Note that the second works even if the first is impossible, which matters, because Amara's employer is not going to abolish night shifts.

14.18 Adwoa Mensah, 78, has osteoporosis and a PTH of 92 pg/mL (normal 15–65) with a serum calcium of 8.9 mg/dL (normal). Nia, 24, has a PTH of 32 pg/mL and a calcium of 9.6 mg/dL. Both women are "normocalcemic." Explain why these are nonetheless completely different physiological states, and what Adwoa's skeleton is paying.

Model answer

Both defend the same variable successfully, but at very different cost — and the cost is what the PTH level reports.

Nia maintains calcium at 9.6 mg/dL with a low-normal PTH: her intestine absorbs calcium efficiently under adequate calcitriol, her kidney reabsorbs it well, her estrogen restrains osteoclasts, and mechanical loading from running signals osteocytes to maintain mineral. Little PTH drive is needed and little bone resorption occurs.

Adwoa maintains calcium at 8.9 mg/dL only by running PTH at nearly three times Nia's level. This is secondary hyperparathyroidism of aging, and it has three simultaneous causes (§16.6): her skin makes roughly a quarter as much vitamin D per unit sun exposure as it did at 20, because epidermal 7-dehydrocholesterol has declined; her declining GFR reduces renal 1α-hydroxylase, so less calcitriol is made from what precursor exists; and her intestine has down-regulated its response to calcitriol. Absorption from the gut therefore falls short, and the only remaining source is the skeleton.

What her skeleton is paying: PTH acting on osteoblasts drives RANK ligand expression, which matures and activates osteoclasts, which dissolve mineralized matrix. Sustained for decades and compounded by the loss of estrogen's restraint on osteoclasts after menopause, this is a continuous net transfer of mineral from bone to plasma. Her osteoporosis is not a disease of bone. It is a disease of the skin, kidney, and intestine, expressed in bone, because the skeleton is the reservoir the body will always raid to defend membrane excitability. Both women are normocalcemic; only one is doing it for free. The single measurement of PTH converts an identical calcium into two different diagnoses — the §16.10 rule again: never read a hormone without reading what controls it, and never read a variable without reading what it costs to hold it there.

Concept Map to Complete

Copy this onto blank paper and fill every bracket from memory before checking the chapter.

                       HORMONE CHEMICAL CLASS
                                │
              ┌─────────────────┴─────────────────┐
      [ ______-SOLUBLE ]                  [ ______-SOLUBLE ]
      peptides, proteins,                 steroids + [ ______ ]
      most amines                                │
              │                                  │
   transport: [ __________ ]         transport: [ ____________ ]
   half-life: [ __________ ]         half-life: [ ____________ ]
   receptor:  [ __________ ]         receptor:  [ ____________ ]
   mechanism: [ __________ ]         mechanism: [ ____________ ]
              │                                  │
              ▼                                  ▼
   G protein → [ _______ ]           complex enters [ _______ ]
             → cAMP → [ _______ ]    binds [ _______ ] element
   amplification ≈ [ ______ ]-fold   → mRNA → [ ___________ ]


                     THE THREE-TIER AXIS
        HYPOTHALAMUS ──[ ______ hormone]──► ANTERIOR PITUITARY
        ANTERIOR PIT. ──[ ______ hormone]──► [ ______ GLAND ]
        that gland ────► effector hormone ──► TARGET TISSUE
                          │
                          └── feeds back to inhibit [ which two? ]

        Peripheral hormone LOW + tropic hormone HIGH = [ ________ ] lesion
        Peripheral hormone LOW + tropic hormone LOW  = [ ________ ] lesion
        Peripheral hormone HIGH + tropic hormone LOW = [ ________ ]


                            THE RAAS
   ↓ renal perfusion → [ _____ ] from [ which kidney cells? ]
        → cleaves [ ____________ ] from the [ which organ? ]
        → angiotensin I → [ which enzyme? ] on [ which organ? ]
        → ANGIOTENSIN II → five targets:
             1 [ ________ ]  2 [ ________ ]  3 [ ________ ]
             4 [ ________ ]  5 [ ________ ]
        → aldosterone acts on [ which nephron segment? ]
             retains [ ___ ] and [ ___ ], excretes [ ___ ] and [ ___ ]
        → ↑ blood volume + ↑ [ ________ ] = ↑ arterial pressure


                     GLUCOSE HOMEOSTASIS
        glucose ↑ → [ ___ ] cell → [ _______ ] → GLUT4 to membrane
        glucose ↓ → [ ___ ] cell → [ _______ ] → liver [ ________ ]

        TYPE 1 = failure of the [ ________ ] box; insulin [ ___ ]
        TYPE 2 = failure of the [ ________ ] box; insulin [ ___ ]

Lab / Self-Exploration

  1. Palpate your own thyroid. Locate the thyroid cartilage (the laryngeal prominence), move one to two finger-widths inferior to the cricoid cartilage, and place your fingertips on either side of the trachea. Swallow. A normal thyroid moves upward with the larynx and is barely palpable. Anything that moves with swallowing is attached to the larynx — which is exactly why clinicians ask patients to swallow while examining a neck lump.
  2. Map your own cortisol rhythm behaviorally. For five days, record the time you wake spontaneously, your subjective alertness at 08:00, 14:00, and 22:00 on a 1–10 scale, and your bedtime. Then plot alertness against clock time. The curve you draw is a rough behavioral readout of the cortisol and core-temperature rhythms. If you work or study at night, compare your curve with someone who does not.
  3. Demonstrate catecholamine action on yourself. Take a resting radial pulse. Then stand up quickly from lying and take it again within 15 seconds. The rise is sympathetic and, after about 30 seconds, adrenal. Note how long it takes to return to baseline — that decay is the clearance of circulating catecholamines, and it is why the hormonal arm outlasts the neural one.
  4. Find the second-messenger logic in your medicine cabinet. Read the mechanism of any inhaler (a beta-2 agonist), any antihistamine, and any topical steroid cream. Sort them into surface-receptor-plus-second-messenger versus intracellular-receptor-plus-gene-activation, then predict which acts within minutes and which takes days. Check the package insert against your prediction.
  5. Test the incretin effect on yourself, carefully and only if you are not diabetic. Eat a fixed carbohydrate breakfast on two mornings — one eaten in ten minutes, one eaten slowly over forty. Record subjective energy and hunger at 60, 120, and 180 minutes. The slower meal produces a lower glucose peak and a longer satiety, and both are partly incretin-mediated. Write the mechanism down before you start, not after.
  6. Read a real thyroid panel. Find any published reference range table for TSH and free T4 (or use §16.5). For each of four combinations — high TSH/low T4, low TSH/high T4, low TSH/low T4, high TSH/high T4 — write the location of the lesion and one disease that produces it. The fourth is the hardest and is worth the effort.

Key Terms

acromegaly · Growth hormone excess after epiphyseal plate closure, enlarging hands, feet, jaw, and soft tissue without increasing height.

adenohypophysis · The anterior pituitary lobe; glandular epithelium derived from Rathke's pouch, controlled by hypothalamic hormones arriving via the hypophyseal portal system.

adrenal cortex · The outer, mesodermal region of the adrenal gland, zoned into glomerulosa (aldosterone), fasciculata (cortisol), and reticularis (androgens).

adrenal medulla · The inner, neural-crest-derived region of the adrenal gland; modified sympathetic postganglionic neurons secreting epinephrine and norepinephrine into the blood.

aldosterone · Mineralocorticoid from the zona glomerulosa that increases sodium and water reabsorption and potassium and hydrogen secretion in the collecting duct.

amplification · The multiplication of a hormonal signal through a second-messenger cascade, typically 10⁶ to 10⁸-fold.

angiotensin II · The active octapeptide of the RAAS; a potent vasoconstrictor that also stimulates aldosterone, renal sodium reabsorption, thirst, ADH release, and cardiovascular remodeling.

antidiuretic hormone (ADH, vasopressin) · Posterior pituitary hormone made in the supraoptic nucleus; inserts aquaporin-2 channels in the collecting duct, concentrating urine.

calcitonin · Parafollicular (C) cell hormone that lowers blood calcium by inhibiting osteoclasts; of minor importance in adult humans.

calcitriol · 1,25-dihydroxyvitamin D, activated in the kidney by PTH-stimulated 1α-hydroxylase; increases intestinal calcium absorption.

colloid · The thyroglobulin-rich material stored in the lumen of a thyroid follicle; the extracellular reservoir of thyroid hormone.

cortisol · The principal glucocorticoid; mobilizes fuel, opposes insulin, is permissive for vascular catecholamine responsiveness, and suppresses inflammation.

Cushing syndrome · The clinical state of glucocorticoid excess: central obesity, thin limbs, striae, hypertension, hyperglycemia, osteoporosis, immunosuppression.

diabetes insipidus · Deficiency of ADH (central) or of renal responsiveness to it (nephrogenic), producing large volumes of dilute urine and hypernatremia.

down-regulation · Loss of target-cell receptors and receptor coupling in response to persistently high hormone levels; the molecular basis of hormone resistance.

endocrine gland · A ductless gland secreting hormones into interstitial fluid and thence to the bloodstream.

erythropoietin · Renal hormone that stimulates red blood cell production in bone marrow in response to tissue hypoxia.

general adaptation syndrome · Selye's three stages of the stress response: alarm (catecholamines), resistance (cortisol), exhaustion (accumulated cost).

glucagon · Alpha-cell hormone that raises blood glucose through hepatic glycogenolysis, gluconeogenesis, and ketogenesis.

GLUT4 · The insulin-dependent glucose transporter of skeletal muscle and adipose tissue; translocated to the membrane by insulin and, independently, by muscle contraction.

growth hormone (GH) · Anterior pituitary hormone promoting protein anabolism, lipolysis, and glucose sparing; drives longitudinal growth indirectly through hepatic IGF-1.

hormone · A chemical messenger secreted into the blood that alters the activity of distant target cells bearing its receptor.

hypophyseal portal system · Two capillary beds in series joined by veins, carrying hypothalamic releasing hormones at high concentration directly to the anterior pituitary.

hypothalamus · The neuroendocrine control center: makes ADH and oxytocin, releases hypothalamic releasing and inhibiting hormones, and houses the suprachiasmatic circadian clock.

insulin · The only hypoglycemic hormone; a beta-cell product that drives GLUT4 to the membrane and switches the body from fuel mobilization to fuel storage.

insulin resistance · Failure of target tissues to respond normally to insulin, producing compensatory hyperinsulinemia; the central lesion of metabolic syndrome and type 2 diabetes.

melatonin · Pineal hormone secreted only in darkness; the chemical signal of biological night, entrained by light through the retinohypothalamic tract.

metabolic syndrome · The clustering of central obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL around a single mechanism of insulin resistance.

negative feedback · The universal endocrine control pattern in which a hormone's effect opposes and therefore terminates the stimulus for its own release.

neurohypophysis · The posterior pituitary lobe; neural tissue containing the axon terminals of hypothalamic neurons, from which ADH and oxytocin are released.

parathyroid hormone (PTH) · Chief-cell hormone that raises blood calcium through bone resorption, renal calcium reabsorption with phosphate excretion, and calcitriol activation.

permissiveness · A hormone interaction in which one hormone must be present for another to exert its full effect, as thyroid hormone is for catecholamines.

pituitary gland (hypophysis) · The pea-sized gland in the sella turcica, comprising two embryologically and functionally distinct lobes.

primary / secondary / tertiary · Localization of an endocrine lesion to the peripheral gland, the pituitary, or the hypothalamus respectively, determined by measuring the peripheral hormone together with its tropic hormone.

renin · An enzyme secreted by juxtaglomerular granular cells in response to falling renal perfusion; cleaves angiotensinogen and is the rate-limiting step of the RAAS.

renin–angiotensin–aldosterone system (RAAS) · The integrated kidney–liver–lung–adrenal loop that defends arterial pressure through vasoconstriction, sodium retention, thirst, and ADH release.

second messenger · An intracellular signaling molecule such as cyclic AMP or calcium, generated when a water-soluble hormone binds its surface receptor.

steroid hormone · A lipid-soluble hormone synthesized from cholesterol, transported bound to carrier proteins, acting on intracellular receptors by direct gene activation.

target cell · A cell bearing functional receptors for a given hormone, and therefore the only kind of cell that hormone can affect.

thyroglobulin · The large iodinated glycoprotein in colloid that constitutes the stored form of thyroid hormone.

thyroid follicle · The functional unit of the thyroid: a sphere of cuboidal follicular cells enclosing a lumen of colloid.

thyroid hormone (T3, T4) · Iodine-containing, lipid-soluble hormones that set basal metabolic rate; T4 is the prohormone and reservoir, T3 the active form produced by peripheral deiodination.

tropic hormone · A hormone whose target is another endocrine gland; also trophic, in that it maintains that gland's mass.

up-regulation · Increase in target-cell receptor number in response to persistently low hormone levels, raising sensitivity.

Next: Chapter 17 · Blood — where the medium every hormone in this chapter travels through is finally examined on its own terms, and where Amara's complete blood count raises three new questions.